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ABSTRACT
Background: Antipsychotic drugs are primary medication for patients suffering
schizophrenia. Although these drugs are effective for the treatment of positive and
negative symptoms, the chronic administration of these drugs is associated with
cognitive deficits, decreased volume of grey matter, and reduced cortical thickness
in schizophrenic patients. Sodium butyrate, one of histone deacetylase 2 (HDAC2)
inhibitors, has been shown to promote synaptogenesis in neurons and reinstate
cognitive function in animal models of neurodegeneration diseases. This study
aimed to examine the side effect and mechanism of olanzapine, one of the most
commonly prescribed antipsychotic drugs, on synaptogenesis in neurons, and the
possible neuroprotective effect of sodium butyrate.
Methods: The SH-SY5Y neuronal cell or primary cortical neurons were treated
with olanzapine, butyrate, or combination of olanzapine and butyrate followed by
the examination of neurite morphology. Neurite morphology, including neurite
length and spine density, was analysed by using the IncucyteZoom system and the
confocal microscopy. The production of reactive oxygen species (ROS) was
determined with flow cytometry and fluorescence microscopy. The western blot
was used to determine the change of sirtuin 1 (Sirt1), p65, p50, HDAC2, and
brain-derived neurotrophic factor (BDNF) protein expression in SH-SY5Y cells.
RT-PCR technique was used to determine the mRNA level of BDNF,
microtubule-associated protein 2 (MAP2), synaptophysin, and postsynaptic density
protein 95 (PSD95) in primary cortical neurons. Moreover, the enzyme activity of
recombinant and SH-SY5Y cells-derived HDAC2 was investigated by using
deacetylase activity assay kits.
Results: The treatment of olanzapine significantly decreased neurite outgrowth and
i

lowered dendritic spine density in SH-SY5Y cells and cortical neurons,
respectively. Furthermore, olanzapine led to oxidative stress and decreased Sirt1
expression, thereby activating the NF-κB signaling pathway. Olanzapine increased
the protein level of HDAC2 and decreased mRNA and protein levels of BDNF.
Furthermore, overexpression of p65, the subunit of NF-κB, resulted in the
upregulation of HDAC2 protein level in SH-SY5Y cells, suggesting that activation
of NF-κB may contribute to HDAC2 upregulation induced by olanzapine. Sodium
butyrate rescued neuronal damages induced by olanzapine. Despite sodium
butyrate did not affect the oxidative stress/Sirt1-NF-κB-HDAC2 pathway, it
blocked the deacetylase activity of HDAC2 significantly and restored the BDNF
expression.
Conclusion: This study suggests that olanzapine can induce neurite lesions.
Furthermore, it unravels the underlying mechanism of olanzapine-induced neurite
lesions involving in the oxidative stress/Sirt -NF-κB -HDAC2 -BDNF pathway.
Also, this study indicates that sodium butyrate, an HDAC2 enzyme inhibitor, has
the neuroprotective effect on the neuronal lesion induced by olanzapine. Since
butyrate has been safely used in the clinical trial of anti-inflammation, my findings
suggest that sodium butyrate can be used to prevent the abnormal synaptogenesis
and cognitive deficits induced by chronic olanzapine treatment in clinical settings.
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CHAPTER 1
Literature review
1. Overview of schizophrenia
Schizophrenia is a heritable psychiatric disorder and affects approximately 1%
of the population worldwide. Symptoms of schizophrenia are manifested late in
childhood or early in adulthood, and are classified into three groups: positive
symptoms, like hallucination, delusion, and other thought disorders, negative
symptoms, such as social withdrawal, lack of motivation and blunted affect, and
cognitive symptoms, such as memory defects and attentional deficits (Dawe et
al., 2009, Ghoshal et al., 2016, Lewis and Lieberman, 2000). The etiology and
pathophysiology of schizophrenia are still not very clear. However, the
pathological feature of schizophrenic patients is shown as losing grey matter and
less synaptic structures on neurons (Glausier and Lewis, 2013). Additionally, the
abnormality in gene and environmental factors are considered as contributors to
schizophrenia. It has been confirmed that schizophrenia is associated with the
mutation of multiple genes by molecular genetic studies, such as genome-wide
association study (GWAS) arrays (Owen et al., 2005, Ripke et al., 2014). Among
these candidate genes, the neuregulin 1 (NRG1), dysbindin-1 (DTNBP1), v-akt
murine thymoma viral oncogene homolog (Akt), and disrupted in schizophrenia
1 (DISC1) are received attention in recent years because of their significance in
neurotransmission, neuroplasticity, and neurodevelopment (Bellon, 2007).

2. Antipsychotics treatment for schizophrenia
The medication for schizophrenia is divided into two groups as first-generation
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antipsychotics (FGA) and second-generation antipsychotics (SGA). The FGA, such
as chlorpromazine and haloperidol, acts as the dopamine D2 receptor antagonist to
reduce positive symptoms (Luft and Taylor, 2006). However, the long-term
medication of FGAs can result in side effects as extrapyramidal side effects (EPSEs)
and hyperprolactinemia (Lally and MacCabe, 2015). To minimize these side effects,
the SGA, such as clozapine, olanzapine, and risperidone, is developed and is
considered as prominent antagonists for the serotonin 5-HT2A receptor combined
with the dopamine D2 receptor (Hill et al., 2010, Thomas and Lewis, 1998). SGAs
have more efficacy on negative symptoms compared with FGAs, whereas it is
reported that SGAs are associated with weight gain and cardiometabolic adverse
effects in schizophrenic patients (Leucht et al., 2009). Olanzapine, a kind of
thienobenzodiazepine derivatives, shows effective therapeutic effects on psychotic
symptoms in schizophrenic patients (Beasley et al., 1996). It is confirmed that
olanzapine can bind with various receptors as dopamine receptors (1~5), serotonin
receptors

(5HT2A/5HT2C/5HT3/5HT6),

muscarinic

receptors,

α1-adrenergic

receptors and histamine H1 receptors (Bymaster et al., 1998, Bymaster et al., 1997,
Roth et al., 1994). It demonstrates that olanzapine has a higher binding affinity with
the serotonin 5-HT2A receptor and the dopamine D2 receptor with occupancy as 70%
and 30%, respectively (Kusumi et al., 2000, Huang et al., 2006).

3. Cognition and synaptogenesis
Cognitive function is defined as the ability to get attention, learning and memory,
speed of information processing, psychomotor ability, and executive functions
(Lawlor, 2002, Moriarty et al., 2011). Cognitive deficits are found in many mental
diseases, including schizophrenia, dementia, and other psychotic disorders, which
2

is associated with the neuropathological process, such as loss of synaptic elements
and alteration of cerebral white matter (Dwork et al., 2007). The neuron consists of
a cell body (soma) and neurites, such as axons and dendrites (Figure 1-1)
(Rochefort and Konnerth, 2012). Synapses are junctions between neurons for
neuronal communication. Dendrites are tree-like structures and are extended from
the soma. Dendritic spines are protrusions in the dendrite for further synaptic
connections and excitatory inputs (Lodish et al., 2008). Dendritic spines are usually
classified as filopodia-liked spines, stubby spines, thin spines, and mushroom
spines. Mushroom spines, as memory spines, can anchor many neurotransmitter
receptors and can exist for few months; whereas thin spines, as learning spines,
contain fewer neurotransmitter receptors and persist for few days (Bourne and
Harris, 2007, Dunaevsky et al., 1999, Ziv and Smith, 1996, Matsuzaki et al., 2001).
The stubby and filopodia-liked spines are dynamic and are considered as immature
spines due to lacking of postsynaptic density proteins (Berry and Nedivi, 2017).
The decreased neurite outgrowth and spine density are associated with cognitive

Figure 1-1 The structure of the neuron. The basic component of a neuron, including dendrites,
a axon, the myelin sheath, the cell body, the nucleus, nodes of Ranvier. Besides, the morphology
of different types of spine is shown.
3

impairment (Huang and Song, 2019). The brain-derived neurotrophic factor
(BDNF), which is an important regulator for neuronal development, synaptic
transmission, and synaptic plasticity, can promote the formation and maintenance
of memory (Garraway and Huie, 2016). A study confirmed that the increased
BDNF in the medium led to stimulation of its receptor tyrosine kinase B (TrkB)
and downstream signaling pathway in rat hippocampal neurons, which promoted
synaptogenesis (Ji et al., 2010). Also, BDNF administration facilitated
neurotransmission and synaptogenesis in pyramidal neurons of rodents (Tyler and
Pozzo-Miller, 2001, Tyler and Pozzo-Miller, 2003). Moreover, the administration
of BDNF-mimetic treatment restored the synaptic plasticity and cognition in mouse
models of Down’s Syndrome (Parrini et al., 2017). Postsynaptic density protein 95
(PSD95) is a scaffolding protein involved in synaptic development and plasticity
(Funke et al., 2005). Synaptophysin is a membrane protein of pre-synapse and plays
an important role in synaptogenesis (Gudi et al., 2017). Microtubule-associated
protein 2 (MAP2) is critical for the improvement of neuromorphogenesis, as the
origination of neurites (Dehmelt and Halpain, 2004). Therefore, alteration of the
neurotrophic factor, as BDNF, and synaptic proteins, as PSD95, synaptophysin, and
MAP2, contributes to neuronal lesions, synapse loss, and cognitive impairments.

4. Chronic treatment of antipsychotic drugs leads to cognitive deficits and
neuronal lesions
Although antipsychotic drugs show efficacy in the treatment of positive and
negative symptoms, the cognitive deficit has been found in schizophrenic patients
and animal models with chronic administration. For example, the lifelong
medication of antipsychotics was associated with poor cognitive performance and
4

decline in verbal learning and memory, which was determined in a
9-year follow-up study (Husa et al., 2014). Also, a significant loss of cortical grey
matter was found in schizophrenic patients with the long-term medication of
antipsychotics in a meta-analysis based on 18 studies (Vita et al., 2015). Besides,
the chronic administration of antipsychotic drugs impaired abilities of short-term
recognition memory and spatial learning in rats (Schröder et al., 2005, Rosengarten
and Quartermain, 2002). Therefore, the cognitive impairment, including the loss in
attention, impairments in executive function, and poor working memory, may be
caused by chronic administration of antipsychotics in schizophrenia. Furthermore,
the treatment of antipsychotics, as haloperidol and clozapine, resulted in shorter
neurite outgrowth and decreased density of synaptic spines in neuroblastoma cells
and primary neurons (Hu et al., 2018, Ibi et al., 2017).

Clinically, clozapine and olanzapine are the most commonly prescribed
medications (Ashcroft et al., 2002, Winckel and Siskind, 2017). Clozapine is
available only for oral administration (Asenjo‐Lobos et al., 2018). It is prescribed
for the schizophrenic patients whose symptoms cannot be controlled with standard
antipsychotic drugs; however, a safe therapeutic dosage range for clozapine has not
been established due to variation in individual responses. Clozapine is a restricted
drug by the US Food and Drug Administration (FDA) that requires periodic
hematological monitoring (Stark and Scott, 2012), as it can result in severe adverse
effects, such as hematological disorders like agranulocytosis (decline in the number
of white blood cells, particularly in neutrophils) (Asenjo‐Lobos et al., 2018). In a
review published in Lancet, the number of participants assigned to the treatment
and clinical trials of olanzapine is the highest compared with that of other
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antipsychotics (Huhn et al., 2019). There are various types of olanzapine
interventions, such as oral administration and intramuscular injection. Clinically,
oral administration of olanzapine is used for schizophrenia, acute treatment of
manic or mixed episodes associated with bipolar I disorder, and maintenance
treatment of bipolar I disorder. The injectable formulation is approved to treat acute
agitation associated with schizophrenia and bipolar I mania. The previous research
has reported that clozapine administration impaired synaptogenesis and cognition
in rodents (Ibi et al., 2017). In this thesis, the direct effects of olanzapine on the
synaptogenesis will be examined in neurons.

5.

Oxidative stress induces cognition deficits and neuronal lesions

The oxidative stress, which can induce cell damages, is defined as a higher
proportion of pro-oxidants compared with antioxidants (Sies, 1997). The reactive
oxygen species (ROS) (pro-oxidants) includes superoxide anion radicals, hydrogen
peroxide, singlet oxygen, ozone, hydroxyl radicals, and organic peroxides.
Moreover, biological antioxidants (glutathione, α-tocopherol, carotenoids, and
ascorbic acid) and antioxidant enzymes (peroxide dismutase, catalases, and
glutathione

peroxidase)

can

react

and

detoxify

the

ROS

(Nathan and Cunningham-Bussel, 2013, Klein and Ackerman, 2003). Mitochondria
is the primary source of ROS, since the superoxide dismutase inside mitochondria
can generate the superoxide and hydrogen peroxide (Loschen et al., 1974, Forman
and Kennedy, 1974, Munro and Treberg, 2017). The brain consumes 20% oxygen,
which is the primary precursor of ROS, to satisfy the high rate of metabolism (Rink
and Khanna, 2011). Besides, the metabolism of the high proportion of oxidized
molecules, such as polyunsaturated fatty acid and oxidized neurotransmitters
6

(dopamine, epinephrine, and norepinephrine), generates a large quantity of ROS in
the brain (Mahadik and Mukherjee, 1996, Halliwell, 2001). Also, the lower level
of antioxidant enzymes in the brain indicates that the oxidative stress easily
occurred and the brain is vulnerable to the ROS (Bošković et al., 2011).

Currently available studies prove that decreased antioxidant defense and higher
ROS level is shown in schizophrenic patients with deficits in executive function
(Bošković et al., 2011, Prabakaran et al., 2004, Gonzalez-Liencres et al., 2014),
which indicates that the oxidative stress is involved in the pathology of
schizophrenia and contribute to cognition dysfunction in schizophrenic patients
(Zhang et al., 2015). In rat models of chronic ischemia, the memory and learning
capacity was impaired with the higher ROS level in the hippocampus and frontal
cortex, however, the administration of ROS scavengers relived that damage (Li and
Zhang, 2015). The rats exposed to ozone (under oxidative stress state) showed
long-term memory deficits and decreased spine density in the hippocampus
(Avila-Costa et al., 1999). Treatment of hydrogen peroxides induced lower cell
viability and decreased neurite outgrowth of SH-SY5Y neuroblastoma cells in a
time-dependent manner (Ashabi et al., 2013). Moreover, oxidative stress caused by
a high saturated fat diet resulted in decreased BDNF expression and induced
cognitive impairments (Wu et al., 2004). Anti-psychotics such as clozapine has
been found to induce oxidative stress in neutrophils of schizophrenic patients
(Fehsel et al., 2005), as well as rat models (Polydoro et al., 2004). Olanzapine also
induces oxidative stress in rats (Todorović et al., 2016); however, whether
olanzapine directly induces neuronal injuries via oxidative stress is still unknown.

7

6. Sirt1 is involved in neurogenesis and mental diseases
Mammalian sirtuins (Sirt1~Sirt7) are nicotinamide adenine dinucleotide (NAD+)
dependent deacetylases with high levels of homology to gene silent information
regulator 2 in Saccharomyces cerevisiae (Nogueiras et al., 2012). It is known that
sirtuins regulate lifespan, gene silencing, DNA repair, and ribosomal DNA
recombination (Wood et al., 2004, Kanfi et al., 2012). Sirtuins belong to class III
histone deacetylases (HDACs), but they do not have zinc atom at catalytic sites,
which indicates that some sirtuins may not have deacetylase activity (Dokmanovic
et al., 2007). Sirt1, which is one of the sirtuin family and exhibits deacetylase
activity, can improve neurodevelopment and ameliorate neurodegenerative
disorders (Herskovits and Guarente, 2014). It has been confirmed that Sirt1
activators (resveratrol and NAD) enhanced the neurite outgrowth in PC12
(pheochromocytoma) cells, while treatment with Sirt1 inhibitors (nicotinamide and
splitomicin) or Sirt1 siRNA impaired the neurite outgrowth (Sugino et al., 2010).
Another study demonstrated that the inhibition of Sirt1 impaired the differentiation
of neural precursor cells (NPCs) into neurons; however, the treatment of Sirt1
activators enhanced the neuronal differentiation (Hisahara et al., 2008). In primary
hippocampal neurons, Sirt1 siRNA resulted in impairments in axon elongation and
branching, but the treatment of Sirt1 vector and activator induced axonogenesis (Li
et al., 2013). Sirt1 inhibition blocked the axon generation in dorsal root ganglion
sensory neurons; besides, Sirt1 overexpression counteracted the impairment in
axon length induced by microRNA-138 (Liu et al., 2013). In Sirt1 knockout mice,
the decreased dendritic branching and arborization were along with cognitive
function defects (Michán et al., 2010). Another study confirmed that the impaired
synaptic plasticity and decreased expression of BDNF were shown in Sirt1
8

knockout mice with cognitive deficits (Gao et al., 2010). These findings indicate
that Sirt1 plays a vital role in the promotion of neurogenesis.

Treatment with resveratrol (Sirt1 activator) or overexpression of Sirt1 ameliorated
the primary neuron death and degeneration in mouse models of dementia (Kim et
al., 2007). Furthermore, it suggested that the Sirt1 deficiency induced the
acetylation of Tau protein, which blocked its ubiquitination and degradation (Min
et al., 2010). Also, Min’s team found that Sirt1 deficiency resulted in the
accumulation

of

phosphorylated

Tau,

which

induced

tau-mediated

neurodegeneration. Knockdown of Sirt1 exacerbated the neurodegeneration in
mouse models of Huntington’s disease; however, the overexpression of Sirt1
ameliorated that effect and increased BDNF expression (Jeong et al., 2012, Jiang et
al., 2011). It is confirmed that the Sirt1 gene is involved in the pathogenesis of
schizophrenia (Kishi et al., 2011). Treatment of resveratrol increased the protein
level of Sirt1 and BDNF and alleviated oxidative stress in the hippocampus of rat
models of schizophrenia induced by MK801(Niu et al., 2020). These findings
above imply that Sirt1 plays a crucial role in the pathogenesis of mental diseases.

7. Interaction between oxidative stress and Sirt1
Previous researches suggest that there is a crosstalk between Sirt1 and oxidative
stress, evidenced by the Sirt1 was upregulated in response to the oxidative stress,
whereas the moderate overexpression of Sirt1 induced the antioxidant system to
ameliorate the oxidative stress (Alcendor et al., 2007). For example, Sirt1
deacetylated the FOXO transcription factor, which stimulated the production of
antioxidant enzymes (superoxide dismutase and catalase) and antioxidants
9

(selenoprotein P and ceruloplasmin) (Klotz et al., 2015, Kobayashi et al., 2005).
Also, Sirt1 can bind and deacetylate the NF-κB to regulate the production of
antioxidants and pro-oxidants (Yeung et al., 2004). Another transcription
factor — Nrf2 is deacetylated by Sirt1, which induces its translocation from the
nucleus into the cytoplasm and terminates the antioxidant defense (Kawai et al.,
2011). Moreover, the Sirt1 shows deacetylase activity at promoters of uncoupling
proteins (UCP2 and UCR3) and suppresses the transcription of UCPs to attenuate
the accumulation of ROS in mitochondria (Bordone et al., 2006, Amat et al., 2007,
Brand and Esteves, 2005). Besides, oxidative stress induces the activation of Jun
N-terminal kinase 1 (JNK1), which results in phosphorylation of Sirt1 at Ser27,
Ser47 and Thr530 residues, and improves the deacetylase activity of Sirt1 (Nasrin
et al., 2009, Kamata et al., 2005). However, persistent stimulation of JNK1 induced
by insulin and glucose results in degradation of Sirt1 (Gao et al., 2011).
MicroRNA-34a stimulated by oxidative stress can bind with the 3’UTR region of
Sirt1 mRNA and inhibit the transcription of Sirt1 (Baker et al., 2016, Yamakuchi
et al., 2008). Treatment of hydrogen peroxide led to the carbonylation on cysteine
residues of Sirt1, which reduced the protein expression and deacetylase activity of
Sirt1 in human lung epithelial cells (Caito et al., 2010).

8. Activation of the NF-κB signaling pathway is involved in neuronal lesions
Nuclear factor kappa B (NF-κB) is a homodimeric or heterodimeric protein
complex, which can act as a transcription factor to regulate cell proliferation,
differentiation, apoptosis, inflammation response and other biological processes
(Donadelli et al., 2000). NF-κB family members, including NF-κB1 (p50/p105),
RelA (p65), NF-κB2 (p52/p100), c-Rel, and RelB, share the Rel Homology Domain
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(RHD) in their sequence (Serasanambati and Chilakapati, 2016). In resting cells,
the NF-κB dimer is sequestered with NF-κB inhibitors (IκB), including IkBα, IkBβ,
IkBɛ, Bcl-3, and precursors of Rel-proteins, at RHD to remain an inactive form in
the cytoplasm (Strickland and Ghosh, 2006). When the NF-κB signaling pathway
is activated, the specific IκB kinases (IKK) is activated to phosphorylate the IκB,
which triggers ubiquitination and degradation of IκB. Then the free NF-κB
translocates into the nucleus, which leads to binding with DNA sequences and
regulation of the transcription (Salminen et al., 2008a). In response to different
stimuli, the NF-κB signaling pathway is divided into the canonical pathway and the
alternative pathway (Figure 1-2) (Dolcet et al., 2005). The canonical pathway is
predominately stimulated by TNF-α, IL-1, and lipopolysaccharide, then the IKK
phosphorylates the IκB, which undergoes ubiquitin-dependent degradation by the
proteasome. The free NF-κB dimer, which consists of p50 with either RelA or

Figure 1-2 The schematic diagram of the activation of the NF-κB signaling pathway. Two
pathways can activate the translocation of NF-κB dimer into the nucleus, as canonical and
alternative pathways. For canonical pathway, the IKK complex phosphorylates IκB and triggers its
degradation by proteasomes. The RelA/p50 complex is free and translocates into the nucleus,
resulting in the regulation of target genes. For alternative pathway, p100 is phosphorylated and
proteolyzed into the p52 mature form before the NF-κB dimer (P52/RelB) translocates into the
nucleus, which regulates the transcription of target genes.
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c-Rel, translocates into the nucleus and acts as the transcription factor. The
alternative pathway is predominately triggered via stimulation of CD40,
lymphotoxin B, and BAFF (B cell activating factor). When the alternative pathway
is stimulated, the NF-κB inducing kinase (NIK) is activated to phosphorylate the
IKK complex. Then the p100, a precursor of Rel-protein, is phosphorylated by the
IKK complex and proteolyzed to generate the mature form (p52), which results in
the liberation of the RelB-p52 complex to regulate the gene transcription
(Serasanambati and Chilakapati, 2016, Dolcet et al., 2005).
The activation of the NF-κB signaling pathway is involved in neuronal lesions. For
example, activation of the NF-κB signaling pathway induced by hydrogen peroxide
led to apoptosis in SH-SY5Y neuroblastoma cells (Larouche et al., 2008, Mendell
et al., 2016), which suggest that oxidative stress may activate the NF-κB signaling
pathway and induce neuronal lesions. In addition, it is demonstrated that the Sirt1
deacetylated p65, a subunit of NF-κB, and blocked its translocation into the nucleus
in HEK 293T cells (Yeung et al., 2004), which suggest that Sirt1 can inhibit the
NF-κB signaling pathway. The activation of cerebral NF-κB signaling pathway
induced decreased basal and apical dendritic spine density, and impaired memory
function in the mouse model of heart failure (Meissner et al., 2015). Moreover, the
overexpression of p65/p50 subunit induced activation of the NF-κB pathway, then
inhibited neurite outgrowth in primary superior cervical ganglion neurons
(Gutierrez et al., 2008). Therefore, the NF-κB pathway mediated by oxidative stress
and Sirt1 may be involved in neuronal lesions.

9. The role of histone deacetylase 2 (HDAC2) in cognitive deficits and
neuronal lesions
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In resting cells, DNA is surrounded by octamer histones (such as an H3/H4 tetramer
and two H2A/H2B dimers) to form the nucleosome (Park and Kim, 2020). During
the process of transcription, the post-translational modification of histones, such as
phosphorylation, methylation, and acetylation, influences the binding between the
transcription factor and DNA sequence (De Ruijter et al., 2003). The acetylation of
histones is regulated by histone acetyltransferases (HATs) and histone deacetylases
(HDACs). HATs can transfer the acetyl group from acetyl-CoA into lysine residues
of the N-terminal of histones, leading to the decreased affinity between histones
and DNA. The hyperacetylation by HATs induces the interaction between
transcription factors and DNA, and increase the gene expression. In contrast,
HDACs remove the acetyl groups from lysine residues at the N-terminal of histones,
which enhances the affinity between DNA and histones. This hypoacetylation by
HDACs leads to a condensed structure of DNA and blocks the gene transcription
(Ito et al., 2000, Peserico and Simone, 2010, Strahl and Allis, 2000).

Histone deacetylases are sorted into classical HDAC family members and
nicotinamide adenine dinucleotide (NAD+)-dependent HDACs (sirtuin family)
based on the difference of conserved deacetylase domain and dependence of NAD
as cofactors (Park and Kim, 2020). The classical HDAC, including class I HDACs,
class II HDACs, and HDAC11, is distinguished based on their similarity with
deacetylases in yeast. Class I HDACs include HDAC 1, 2, 3, 8, which are similar
to the transcriptional regulator RPD3 in the yeast, and are inside the nucleus. Class
II HDACs are homogenous with the HDA1, which is a deacetylase found in yeast.
The class II HDACs is divided into class IIa (HDAC 4, 5,7, 9), which can move
between the nucleus and cytoplasm in response to the cellular signals, and class IIb
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(HDAC 6, 10), which mainly locates in the cytoplasm. The HDAC11 is similar to
HDAC3 and HDAC8, but it contains a catalytic domain in the N-terminal and
locates in the nucleus (Bjerling et al., 2002, Timmermann et al., 2001, Xu et al.,
2011). HDAC2 is one of the class I HDACs and cannot be cytosolic because of
lacking the nuclear export signal (Johnstone, 2002). When HDAC2 is recruited to
form the multiprotein complex, such as Sin3, nucleosome-remodeling deacetylase
complex (NuRD) and Co-REST, in response to transcription factors, the
deacetylase activity of HDAC2 is enhanced by polypeptides in that complex, such
as MTA2 and Sds3p (Lechner et al., 2000, Zhang et al., 1999, Delcuve et al., 2012).
Besides, the expression and activity of HDAC2 can be mediated by
post-translational modification at the C-terminal domain part, such as
phosphorylation, acetylation, ubiquitination, nitrosylation, and carbonylation
(Segré and Chiocca, 2011).
The previous study suggests that the total HDAC expression is lower in the
dorsolateral prefrontal cortex of schizophrenia with cognitive deficits, but higher in
the cerebral white matter, pons, and cerebellum (Gilbert et al., 2019). This indicates
that the abnormal HDAC expression may relate to adverse effects in cognition.
Besides, chronic administration of clozapine induced the higher mRNA level of
HDAC2 in the frontal cortex of mice, which is an important brain region for
cognition (Kurita et al., 2012). Moreover, the HDAC2 overexpressed mice showed
deficits in memory formation with decreases in dendritic spine density, synapse
number, and synaptic plasticity, whereas learning capacity and working memory
were improved in the HDAC2 knockout mice and the mice with HDAC2 deletion
in postmitotic forebrain neurons (Morris et al., 2013, Guan et al., 2009). Also,
genetic silencing of HDAC2 protein rescued cognitive deficits and reinstated the
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synaptic plasticity in rodent models of Pitt-Hopkins syndrome and Alzheimer’s
diseases (Kennedy et al., 2016, Gräff et al., 2012, Yamakawa et al., 2017).
Cognitive deficits (short-term spatial memory) and synaptogenesis impairments
induced by antipsychotic drugs, clozapine, was ameliorated in HDAC2 knockout
mice (Ibi et al., 2017). Besides, HDAC inhibitors (sodium valproate, vorinostat,
LBH589, MS-275) administration restored the cognitive function in the animal
models of aging, Alzheimer’s disease, Huntington’s disease and depression (Benito
et al., 2015, Kilgore et al., 2010, Hockly et al., 2003, Siebzehnrübl et al., 2018,
Covington et al., 2009). Previous researches indicate that the overexpression of
HDAC2 induced NF-κB may contribute to neuronal lesions. Both the activation of
the NF-κB signaling pathway and overexpression of HDAC2 can induce neuronal
lesions (Gutierrez et al., 2008, Guan et al., 2009). The activation of the NF-κB
signaling pathway promotes binding between the NF-κB transcription factor and
HDAC2 promoter, resulting in overexpression of HDAC2 expression (Ibi et al.,
2017). Moreover, Guan ’s team demonstrated that HDAC2 deacetylated the histone
3 or histone 4 at the BDNF promoter, which inhibited the BDNF expression in
HDAC2-overexpressed mice. These findings indicate that BDNF expression could
be downregulated by the activation of the NF-κB signaling pathway and HDAC2
overexpression.

10. Short chain fatty acids as HDAC inhibitors contribute to the
enhancement of cognition and synaptogenesis
The HDAC inhibitor is classified into four types, as hydroxamic acids (TSA,
SAHA), short-chain fatty acid (butyrate, propionate), cyclic tetrapeptides/epoxides
(Trapoxin), and benzamides (CI-994, MS-275) (De Ruijter et al., 2003). The
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treatment of SAHA improved memory deficits and enhanced synaptic plasticity in
HDAC2 overexpressed mice (Guan et al., 2009). It is demonstrated that the chronic
administration of SAHA upregulated the signal pathway related to the neurogenesis
and synaptogenesis in the frontal cortex of mice (de la Fuente Revenga et al., 2018).
The administration of CI-994 enhanced the synaptic plasticity and synaptogenesis
in the hippocampus of mice (Gräff et al., 2014). Dietary short chain fatty acids
(SCFAs), including butyrate, propionate, and acetate, are metabolites produced by
the gut microbiome on fermentable fibers (Kim et al., 2018, Silva et al., 2018,
Soliman and Rosenberger, 2011). SCFAs can serve as HDAC inhibitors. For
example, butyrate is one of the effective inhibitors against HDAC with 80%
inhibitory efficiency, while the propionate only has 60% (Kasubuchi et al., 2015).
It is confirmed that two molecules of butyrate can occupy the pocket, which is a
hydrophobic cleft containing a zinc atom, on the surface of HDACs, and inhibit the
deacetylase activity of HDACs (Davie, 2003). In mouse models of dementia,
injection of butyrate reinstated learning and long-term memory ability, and
enhanced the protein level related to the formation of synapse and dendrites
(Fischer et al., 2007). The administration of sodium butyrate improved behavioral
despair in mouse models of depression and upregulated BDNF transcription in the
frontal cortex (Schroeder et al., 2007). Sodium butyrate has shown inhibition
effects of recombinant HDAC2 (Bradner et al., 2010, Vogelauer et al., 2012,
Kilgore et al., 2010). However, the inhibition effect of sodium butyrate in neurons
has not been investigated.

11. Summary
Although antipsychotic drugs have beneficial effects on the control of psychotic
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symptoms in schizophrenic patients, many clinical records and studies imply that
long-term and higher dosage of antipsychotics may induce cognitive deficits in
schizophrenic patients and animal models. Moreover, it is reported that lifetime
intake of antipsychotics induces the loss of cortical grey matter volume.
Furthermore, animal studies indicate that the cognitive defects caused by
antipsychotic drugs may be due to decreases in neurite outgrowth and mature
dendritic spine density. The previous study suggest that the oxidative stress and
alteration of Sirt1, NF-κB signaling pathway, and HDAC2 results in cognitive
deficits and neuronal lesions. However, it is unknown if these molecules are
involved in antipsychotic drugs induced neuronal lesions. Sodium butyrate is one
of SCFAs and inhibits the deacetylase activity of HDAC2. Studies have been
reported the neuroprotection of the sodium butyrate, such as the promotion of
neurite outgrowth, enhancement of synaptogenesis, and elevation of BDNF
expression. However, it is unknown that if butyrate can attenuate neuronal lesions
induced by antipsychotic drugs.

12. Aim and hypothesis
This project aimed to examine if olanzapine could induce neuronal lesions and alter
ROS level, Sirt1 expression, NF-κB signaling pathway, and HDAC2 expression.
Furthermore, the effect and underlying mechanism of sodium butyrate in the
prevention of neuronal damages induced by olanzapine were examined.
We hypothesize that olanzapine can result in neuronal damages, and induce
oxidative stress, lower level of Sirt1, activation of NF-κB signaling pathway and
overexpression of HDAC2 (Figure 1-3). Furthermore, the treatment of sodium
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butyrate may attenuate neuronal lesions induced by olanzapine via the inhibition of
oxidative stress, the elevation of decreased Sirt1 expression, suppression of the
activated NF-κB signaling pathway, blocking of deacetylase activity of HDAC2
and inhibition of overexpressed HDAC2.

Figure 1-3 The proposed mechanism of neurite lesions induced by olanzapine. The oxidative
stress and downregulated Sirt1 induced activation of the NF-κB signaling pathway, thereby
overexpression of HDAC2 and downregulation of BDNF, which resulting in neurite lesions.
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CHAPTER 2
Olanzapine activates NF-κB/ HDAC2 pathway and induces
neuronal lesions

Introduction
Schizophrenia is a heritable psychotic disorder and affects about 1% population
around the world. Antipsychotic drugs are the widely used medication for
schizophrenic patients with significant efficacy in positive symptoms, like
delusions and hallucinations, and negative symptoms, as social withdraw and lack
of motivation (Leucht et al., 2009, Lally and MacCabe, 2015). Both first-generation
antipsychotics (FGAs) and second-generation antipsychotics (SGAs) relieved
psychotic symptoms (Miyamoto et al., 2012). However, a 9-year follow-up study
revealed that the cognitive deficits, as poorer verbal learning and working memory,
occurred in schizophrenic patients with chronic administration of antipsychotic
drugs (Husa et al., 2014). Also, the magnetic resonance images showed that the
cortical grey matter volume and thickness were decreased in schizophrenic patients
with chronic administration of antipsychotic drugs (Vita et al., 2015, van Haren et
al., 2011). In animal studies, the deficit in short-term memory and decreased
cortical volume were showed in rats with chronic treatments of antipsychotic drugs
(Rosengarten and Quartermain, 2002, Schröder et al., 2005, Vernon et al., 2011).
These findings suggest that decreased dendritic spine density and decreased neurite
outgrowth may contribute to the cognitive impairments in schizophrenia (Glausier
and Lewis, 2013, Huang and Song, 2019). Neuronal lesions induced by
antipsychotic drugs, such as haloperidol and clozapine, were evidenced by
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decreases in neurite outgrowth, mature spine density, and spine associated protein
expression (spinophilin) in either neurons and animals (Ibi et al., 2017, Hu et al.,
2018, Lidow et al., 2001, Ukai et al., 2004). Brain-derived neurotrophic factor
(BDNF) is one of the neurotrophins and promotes neurite outgrowth and dendritic
spine density (Ji et al., 2010). After the administration of antipsychotic drugs for
more than 12 weeks, the serum level of BDNF decreased significantly in
schizophrenia compared with that of healthy controls (Grillo et al., 2007). However,
the molecular mechanism of antipsychotic drugs-induced neurite lesion and BDNF
deficits is still not clear.

Sirtuin 1 (Sirt1) is one of the nicotinamide adenine dinucleotide (NAD+)-dependent
deacetylases, which can regulate the neurite outgrowth and dendritic spine
morphology (Sugino et al., 2010, Codocedo et al., 2012). The Sirt1 knockdown
mice showed poorer memory performance and impaired spatial learning with
decreased spine density and downregulated BDNF expression in the brain region
of the hippocampus (Gao et al., 2010). Another study demonstrated the decreased
branch point, dendritic length, and synaptic complexity in Sirt1 knockout mice
(Michán et al., 2010). It was confirmed that schizophrenic patients with SGAs
medication showed decreased plasma levels of BDNF and Sirt1 (Fang et al., 2019).
Therefore, whether the expression of Sirt1 and BDNF altered by antipsychotic
drugs involved in neuronal lesions requires further investigation.

Oxidative stress is caused by the imbalance between toxic reactive oxygen species
(ROS, pro-oxidants) and antioxidants. Also, ROS is predominately generated from
mitochondria (Muller, 2000). It has been confirmed that the higher level of ROS in
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plasma, lower levels and decreased catalytic activity of antioxidant enzymes in
plasma, and declined BDNF level in serum were found in schizophrenic patients
compared with the control group (Gonzalez-Liencres et al., 2014, Zhang et al.,
2015). Also, schizophrenic patients with administration of antipsychotic drugs for
over six months showed the lower antioxidant level in plasma and cognitive
impairments, as deficits in attention and immediate memory (Zhang et al., 2012).
Moreover, oxidative stress induced by the treatment of hydrogen peroxide
decreased neurite outgrowth in primary retinal ganglion cells (Hong et al., 2014).
These findings indicate that oxidative stress may be involved in the antipsychotic
drug-induced neuronal lesions.

Nuclear factor-κappa B (NF-κB) is one of the transcription factors and regulates
apoptosis and inflammation. The inactive form of NF-κB is comprised of p65/p50
subunits (transcription factor dimer) and the NF-κB inhibitor (IκB) (Mattson and
Camandola, 2001). Phosphorylation of IκB induces its ubiquitination and
degradation, which results in the liberation of the p65/p50 complex. Furthermore,
phosphorylation of the p65 subunit leads to the translocation of NF-κB into the
nucleus to regulate the transcription of target genes (Huang et al., 2010). In addition,
researchers found that oxidative stress and Sirt1 inhibition can stimulate the
translocation of NF-κB directly (Gough and Cotter, 2011, Yeung et al., 2004). It is
known that there is the interaction between Sirt1 and oxidative stress, as Sirt1
stimulates the antioxidant expression and ROS regulates the expression and activity
of Sirt1 (Salminen et al., 2013). It is confirmed that the activation of the NF-κB
pathway led to decreased expression of proteins related to neurite outgrowth and
synaptic plasticity, including BDNF, synaptophysin, and PSD95, in hippocampal
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neurons (Zhang et al., 2020). With four weeks of treatment with risperidone, one of
SGAs, first-episode schizophrenic patients showed hyperactivation of NF-κB
pathway in peripheral blood mononuclear cells (Song et al., 2009). Therefore, the
interplay between oxidative stress and Sirt1 may be involved in the activation of
the NF-κB signaling pathway in the cell model of antipsychotic drug-induced
neuronal lesions.

Histone deacetylase 2 (HDAC2), one of class I HDAC enzymes, can remove the
acetyl groups from lysine residues of histones. HDAC2 is involved in the inhibition
of synaptic excitation and synapse formation (Hanson et al., 2013). For example,
the overexpressed HDAC2 in hippocampal neurons decreased dendritic complexity
and reduced dendritic spine density, especially in mushroom-shaped spine
involving in memory performance (Liu et al., 2017). Moreover, the HDAC2
overexpressed mice showed learning and spatial working memory impairments
with decreased synaptic spine density (Guan et al., 2009). Chronic administration
of clozapine (SGA) increased HDAC2 expression and lowered mushroom-shaped
spine density in mice (Ibi et al., 2017). Moreover, knockdown of HDAC2 increased
the mRNA level of BDNF in SH-SY5Y cells (Sartor et al., 2019). Therefore,
HDAC2 may be involved in the reduction of BDNF expression and neurite lesions
induced by antipsychotic drugs.

The SH-SY5Y cell line is one of the most commonly used neuroblastoma cell lines
for neuroscience research (Kovalevich and Langford, 2013). The differentiated
SH-SY5Y cell represents neuronal properties, such as extensive outgrowth neurites
and increased expression of BDNF related to the neuritogenesis (Cheung et al.,
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2009). By using this cell model, we examined the direct effect of different
concentrations of olanzapine, one of the most commonly prescribed antipsychotic
drugs (Ashcroft et al., 2002), on neurite outgrowth. The underlying mechanism
associated with ROS, Sirt1, NF-κB, HDAC2, and BDNF were also examined in
response to olanzapine in the neurons.

Materials and Methods
1. Cell culture and treatment
The undifferentiated neuroblastoma cell line SH-SY5Y was established in Prof.
Huang’s lab, the University of Wollongong, Australia. The SH-SY5Y cell was
cultured in Dulbecco’s Modified Eagle Medium mixed with F12 supplementation
(DMEM/F12, Life Technologies) with 10% heat-inactivated fetal bovine serum
(FBS, Gibco), and 1% penicillin-streptomycin (P/S, Thermofisher) under the
condition of 37°C in 95% air/5% CO2. For differentiation, the cell was seeded in
the culture plate, which was coated with MaxGel™ ECM (1:100, E0282, Sigma
Aldrich) diluted in cold medium without serum for one-hour incubation. The
following day, the medium was replaced with DMEM/F12 containing 10μM
retinoic acid (RA, R2625, Sigma Aldrich), 1% FBS, and 1% P/S for 24 hours. The
differentiated neuroblastoma cell was exposed to different concentrations of
olanzapine (11937, Cayman Chemical). The neurite length for SH-SY5Y cells was
determined with the real-time IncucyteZoom System and analysed by Neurotracker
software (Essen BioScience). The stock solution of olanzapine and RA were
dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich, St Louis, MO, USA)

2. MTT assay
For each well of 96 well plates, two thousand SH-SY5Y cells were seeded. After
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24 hours of differentiation, neuroblastoma cells were exposed to 0, 0.025, 0.05,
0.075, 0.1, 0.125, 0.15, 0.3, 0.5mM olanzapine for 24 hours, 10μl 5mg/ml
3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT, 21795,
Cayman Chemical) stock solution was added into each well containing 100μl fresh
medium and incubated for 4 hours at 37°C. After the supernatant was replaced by
200μl DMSO in each well, the plate was put in an orbital shaker for 15 minutes.
The absorbance at the wavelength of 590nm was determined by SpectraMax
Plus384 absorbance microplate reader (Molecular Devices). The cell viability was
calculated as the percentage of fluorescence intensity of olanzapine-treated cells
relative to that of the control group.

3. Gene transfection
The pCMV4 NF-κB p65 plasmid (RRID: Addgene_21966) and pCMV4 NF-κB
p50 plasmid (RRID: Addgene_21965) were gifts from Warner Greene (Ballard et
al., 1992). The SH-SY5Y cell was transfected by using lipofectamine™ 2000
transfection Reagent (11668019, Invitrogen) following the manufacturer’s
instruction. Briefly, SH-SY5Y cells were seeded in 6 well plates and incubated
overnight. The 4μg plasmid and the 10μl lipofectamine reagent were separately
mixed with 250μl DMEM/F12 medium without serum and incubated at room
temperature for 5 minutes. Then the diluted plasmid and lipofectamine reagent were
mixed gently and incubated for another 20 minutes. The mixture was added into
each well containing 2ml fresh culture medium. After the incubation for 6 hours,
the transfection medium was replaced by the fresh culture medium for 24 hours to
overexpress the transgenic protein.
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4. Western blot
For each well of 6 well plate, a total of 5ｘ105 SH-SY5Y cells were seeded and
differentiated for 24 hours. After SH-SY5Y cells were treated with different
concentrations of olanzapine and lysed with homogeneous buffer (Appendix), the
lysate was put on the ice for one hour. Then, the supernatant after centrifugation of
5 minutes at 5000rpm was stored at -80°C. The protein concentration for each
sample was determined by using the DC-protein assay kit (500-0116, Bio-rad) and
detected with SpectraMax Plus384 absorbance microplate reader at the wavelength
of 750nm. Laemmli buffer mixed with 12μg protein derived from SH-SY5Y cells
was heated at 95°C for 5 minutes. The sample was loaded into the 10% SDS-PAGE
gels (5678025, Bio-rad) for separation (120 voltage for 80 minutes at room
temperature), and then transferred into polyvinylidene Difluoride (PVDF)
membranes (1620177, Bio-rad) (100 voltage for 60 minutes at 4°C). The membrane
was blocked with 5% skim milk in TBST buffer containing 150 mM NaCl, 10 mM
Tris, and 0.075% Tween‐20 (pH 7.5), at room temperature for 1 hour. The
membrane was incubated with primary antibody as HDAC2 (3F3), NF-κB p65
(D14E12), NF-κB1 p105/p50 (D4P4D), Sirt1 (1:1000, #5113, #8242, #24961, Cell
Signaling Technologies), BDNF (N20) (1:200, sc-546, Santa Cruz Biotechnology),
p-NFκB p65 Antibody (Ser 536) (1:200, sc-33020, Santa Cruz),and anti-β-actin
(1:3000; Millipore) dissolved in 1% skim milk in TBST buffer at 4°C overnight.
The secondary antibody as goat anti-mouse (1:3000, 31460, Invitrogen) and goat
anti-rabbit (1:3000, AP308P, Millipore) was added into the membrane for 1 hour at
room temperature. The membrane was detected by using the Enhanced
Chemiluminescence (ECL) western blotting detection reagent (GERPN2209, GE
Healthcare) under the Amersham Gel Imager (GE Healthcare). The density of
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bands was analysed with Quantity One Software (Bio-Rad).

5. Detection of reactive oxygen species (ROS) levels
The intracellular and mitochondrial ROS levels were measured by using
2’,7’-Dichlorofluorescein diacetate (DCFDA, 20656, Cayman Chemical), and
Mitosox (M36008, Thermofisher), respectively. In brief, after 1ｘ105 SH-SY5Y
cells were seeded in each well of 12 well plate and treated with 100μM olanzapine
for 24 hours and then stained with 10μM DCFDA and 5μM Mitosox dissolved in
phosphate-buffered saline (PBS) for 30 minutes and 15 minutes in the dark,
respectively. After washed three times, the fluorescence was detected by the Accuri
C6 flow cytometer (BD Bioscience), and stained cells were imaged by using the
20X DMI8 Fluorescent Microscope (Leica).

6. Statistics
GraphPad Prism 5 (GraphPad Software) was used for statistical analysis. The
one-way analysis of variance (ANOVA) followed by Turkey’s post hoc test was
used for comparisons of multiple groups. The analysis between two groups was
used the unpaired t-test for comparisons. The Data was shown as mean ± SEM, and
p<0.05 was considered as a significant difference.

Results
1. Olanzapine induces impairments in neurite outgrowth in SH-SY5Y cells
Firstly, MTT assay was used to determine the cell viability of SH-SY5Y cells with
the treatment of olanzapine (0μM to 500μM) for 24 hours. Olanzapine affected
SH-SY5Y cell viability in a dose-dependent manner, but low doses of olanzapine
(lower than 150μM) had no significant effects on cell viability (Figure 2-1A). To
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investigate whether the olanzapine can induce lesions in neurite outgrowth, the
neurite length was real-time measured by Incucyte after SH-SY5Y cells treated
with olanzapine (<150μM) for 24hours. The neurite length was shortened by
olanzapine in a dose-dependent manner (Figure 2-1B). Compared with the control
group, the neurite length was reduced to about 74%, 70%, 57%, 32%, 30% after
treatment with olanzapine at 25μM, 50μM, 75μM, 100μM, and 125μM,
respectively. Also, the representative image showed that neurite outgrowth in

Figure 2-1 Olanzapine (Olan) shortens the neurite length but does not affect cell viability of
SH-SY5Y cells. A) Norminalized cell viability of SH-SY5Y cells exposed to different
concentrations of olanzapine ranging from 0 to 0.5mM for 24 hours. The data was analysed by
one-way ANOVA and shown as mean ± SEM. N = 6. ***p < 0.001, versus the control group. B)
The change of neurite length of SH-SY5Y cells treated with different concentrations of olanzapine
for 24 hours. The data was shown as mean ± SEM and analysed by one-way ANOVA. N = 12.
***p < 0.001, versus the control group. C) Representative images of SH-SY5Y cells treated with
olanzapine for 24 hours. Scale Bar = 150µm.
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SH-SY5Y cells was significantly affected after the treatment with 100μM
olanzapine for 24 hours compared with the control group (Figure 2-1C). These
results suggest that olanzapine (<150μM) can impair the neurite outgrowth in
neurons, although it does not induce neuron loss.

2. Olanzapine results in oxidative stress and downregulation of Sirt1 in
SH-SY5Y cells
Oxidative stress has been reported to be associated with neurite outgrowth lesions
and impaired neurogenesis (Fukui et al., 2012, Suzukawa et al., 2000, Yuan et al.,
2015). Since olanzapine-induced neurite lesions were observed, the oxidative stress
marker, the level of ROS, was examined in SH-SY5Y cells after the treatment of
olanzapine. The intracellular and mitochondrial ROS biomarker, DCFDA and
Mitosox, were used. After treatment with 100μM olanzapine for 24 hours, the
fluorescence intensity of DCFDA significantly increased by 50% approximately in
SH-SY5Y cells examined by flow cytometry (Figure 2-2A). The intracellular ROS
accumulation induced by olanzapine was further confirmed by the measurement of
fluorescence intensity of DCFDA in neurons by the fluorescence microscopy
(Figure 2-2C). The fluorescence intensity of Mitosox detected by flow cytometry
and fluorescence microscopy was higher in olanzapine-treated cells compared with
the control group, indicating olanzapine increased ROS in mitochondria
(Figure2-2B, D). It is reported that Sirt1 is negatively affected by ROS
accumulation (Chen et al., 2013). We further found that the Sirt1 level significantly
decreased by 30% approximately after olanzapine treatment in SH-SY5Y cells
compared with the control group (Figure 2-2E). These results suggest that
olanzapine can induce oxidative stress in the neurons with increased ROS
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production and decreased Sirt1 expression.

Figure 2-2 Olanzapine (Olan) induces oxidative stress and decreases Sirt1 expression. The
quantification of fluorescence intensity of olanzapine-treated SH-SY5Y cells stained with A)
DCFDA (FITC) and B) Mitosox (PE) detected by flow cytometry. The corresponding histogram of
flow cytometry was shown. Black line, the control group, red line, the olanzapine group.
N = 4. The data was shown as mean ± SEM and analysed by unpaired t-test. *p < 0.05,
***p < 0.001, versus the control group. Representative images of olanzapine-treated SH-SY5Y cells
stained with C) DCFDA and D) Mitosox detected by the fluorescence microscopy. Scale
bar = 100μm. E) The change of protein level of Sirt1 in SH-SY5Y cells after treatment with
olanzapine for 24 hours. The data was shown as mean ± SEM and analysed by unpaired t-test.
N = 4. *p < 0.05, versus the control group. F) The presentative image of the western blot of Sirt1
protein.
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3. Olanzapine increases the NF-κB level in SH-SY5Y cells
The oxidative stress markers ROS have been reported to regulate the NF-κB
signaling pathway (Salminen et al., 2013). Following the finding that
olanzapine-induced oxidative stress, the protein expression of NF-κB subunits, as
p50 and p65, were examined by western blot in SH-SY5Y cells. The protein level

Figure 2-3 Olanzapine (Olan) stimulates the upregulation of p65 and phosphorylated p65.
The quantification of the protein level of A) p65, B) p50 in SH-SY5Y cell after treatment with
different concentrations of olanzapine for 24 hours. The data was shown as mean ± SEM and
analysed by one-way ANOVA. N = 4. *p < 0.05, **p < 0.01, versus the control group. C)
Representative images of western blot of p65 and p50 protein. D) The change of protein level of
phosphorylated p65 in SH-SY5Y cells exposed to olanzapine for 24 hours. N = 4. Data was shown

as mean ± SEM and analysed by one-way ANOVA. *p < 0.05, versus the control group. E)
The representative image of the western blot of the phosphorylated p65.
30

of p65 was significantly increased after olanzapine treatment for 24 hours at 100μM
and 125μM (Figure 2-3A, C). However, the p50 protein level was not significantly
affected by olanzapine (Figure 2-3B, C). Furthermore, the phosphorylated p65
increased significantly in neuroblastoma cells with the treatment of 100μM
olanzapine (Figure 2-3D, E), suggesting the increased translocation of NF-κB
transcription factor into the nucleus.

4. Olanzapine increases HDAC2 expression in SH-SY5Y cells
It has been reported that the HDAC2 protein level can be regulated by the NF-κB
pathway (Ibi et al., 2017). The results showed that olanzapine treatment at 100μM
and 125μM increased the HDAC2 protein level in SH-SY5Y cells (Figure 2-4A,
B). Next, p65 and p50 plasmids were transfected into SH-SY5Y cells to investigate
if NF-κB could regulate the HDAC2 expression. Both upregulation of p65 and
p65/p50 expression significantly increased the HDAC2 level by 50%
approximately compared with the control group (Figure 2-4C, D). However, when
cells were transfected with p50 plasmid only, there was no difference in HDAC2
level compared with the control group. Overall, these results indicate that the
NF-κB subunit, p65, may contribute to the overexpression of HDAC2 protein
induced by olanzapine in neurons.
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Figure 2-4 Olanzapine induces overexpression of HDAC2 mediated by p65. A)
Quantification of protein level of HDAC2 in SH-SY5Y cells treated with different
concentrations of olanzapine for 24 hours. The data shown as mean ± SEM and analysed by
one-way ANOVA. N = 4. *p < 0.05, versus the control group. B) Representative images of
western blot of HDAC2 protein. C) Quantification of HDAC2 expression in SH-SY5Y cells
after transfection with C-vector, p65 plasmid, p50 plasmid, and p65/p50 plasmids for 24 hours.
Data was shown as mean ± SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, versus
the C-vector group. D) Representative images of western blot of HDAC2, p65, and p50 in
transfected SH-SY5Y cells.
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5. Olanzapine decreases BDNF level in SH-SY5Y cells
Previous researches have shown that HDAC2 downregulates the brain-derived
neurotrophic factor (BDNF), which is important for neurite outgrowth (Jain et al.,
2013, Hacioglu et al., 2016). Since olanzapine impaired neurite outgrowth with
increased HDAC2 expression, the BDNF level in response to olanzapine in
SH-SY5Y cells was examined by western blot. Olanzapine decreased the BDNF
protein level in a dose-dependent manner (Figure 2-5A, B). After olanzapine
treatment at 100μM and 125μM for 24 hours, the BNDF protein dropped to about
70% and 65%, respectively, compared with the control group.

Figure 2-5 Olanzapine (Olan) decreases the BDNF expression in SH-SY5Y cells. A)
Quantification of protein level of BDNF in SH-SY5Y cells treated with different concentrations
of olanzapine for 24 hours. Data was shown as mean ± SEM and analysed by one-way ANOVA.
N = 4. *p < 0.05, **p < 0.01, versus the control group. B) Representative images of western blot
of BDNF protein.

Discussion
Using the SH-SY5Y cell model, we showed that olanzapine treatment decreased
neurite outgrowth and BDNF protein expression in a dose-dependent manner.
Concurrently, olanzapine induced both intracellular and mitochondria ROS
accumulation, decreased expression of Sirt1 protein, activated the NF-κB signaling
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pathway, and upregulated HDAC2 protein expression. These findings suggest that
olanzapine has direct effects on neurons to induce neuronal lesions.

It has been reported that long-term administrations of antipsychotics induced
cognitive deficits, such as impairments in verbal learning, spatial learning and
working memory in schizophrenic patients or animal models (Elie et al., 2010,
Husa et al., 2014, Nielsen et al., 2015, Rosengarten and Quartermain, 2002,
Skarsfeldt, 1996). In the clinical study, the volume of cortical grey matter was
decreased in schizophrenia patients with chronic administration of antipsychotic
drugs (Vita et al., 2015). In an animal study, the eight weeks’ administration of
olanzapine and haloperidol reduced cortical thickness and volume in rats (Vernon
et al., 2014). Besides, chronic clozapine treatment impaired synaptic spine in
cortical neurons of mice (Ibi et al., 2017). However, the effect of antipsychotics,
especially olanzapine, on neurite morphology, have rarely been investigated in
neurons. Importantly, the present study demonstrated that olanzapine directly
decreased neurite outgrowth in SH-SY5Y neurons. Overall, these findings indicate
that olanzapine and other SGAs treatment induced neurite deficits, which may
contribute to cognitive deficits in clinical usage.

It was reported that oxidative stress led to the disruption of neurite morphology and
cytoskeletal structures in human cortical neurons (Allani et al., 2004). In the present
study, the treatment of olanzapine for 24 hours induced ROS production both in
cellular and mitochondrial levels in SH-SY5Y cells. Our result is supported by a
previous study in which olanzapine triggered oxidative stress and induced
autophagy to clear damaged mitochondria in SH-SY5Y cells (Vucicevic et al.,
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2014). Furthermore, olanzapine administration for two weeks induced oxidative
stress, evidenced by the decreased total antioxidant amount and the increased total
oxidant amount in the liver of rats (Bilgic et al., 2017). Administration of clozapine
for 28 days increased mitochondrial ROS level and protein carbonyls (oxidized
protein, another biomarker for oxidative stress) in the hippocampus of rats
(Polydoro et al., 2004, Schröder et al., 2005). Oxidative stress dramatically induced
a loss of learning and memory function in mice, while ROS scavengers prevented
cognitive impairments (Kamsler and Segal, 2003, Liu et al., 2003). Therefore,
antipsychotics induced oxidative stress in neurons may contribute to neurite
outgrowth lesions, thereby inducing cognitive impairments.

Sirt1 is essential for neurodevelopment and neurogenesis (Herskovits and Guarente,
2014). It is reported that excessive ROS level results in inhibition of Sirt1 activity
and downregulation of the mRNA and protein level of Sirt1 (Nasrin et al., 2009,
Yamakuchi et al., 2008, Hulsmans et al., 2011), while, the Sirt1 deacetylates the
specific transcriptional factors to regulate the antioxidant gene expression (Pardo
et al., 2011, Hori et al., 2013), suggesting there is a crosstalk between Sirt1 and
ROS. Consistently, in the present study, we not only found olanzapine increased
ROS level, but also found the Sirt1 level significantly decreased in SH-SY5Y cells.
It was reported that inhibition of Sirt1 by siRNA induced shorter neurite length,
decreased branch numbers, and lower dendritic spine density in neurons (Hisahara
et al., 2008, Guo et al., 2011). In Sirt1 knockdown mice, memory performance and
spatial learning were damaged (Gao et al., 2010). In contrast, overexpressed Sirt1
in neurons improved neuronal cell survival (Kim et al., 2007). Also, they found that
the resveratrol, a Sirt1 activator, prevented the impairment in learning capability in
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mouse models of Alzheimer’s disease. Therefore, oxidative stress and
dysregulation of Sirt1 may be interfered with each other to mediate neurite deficits
induced by olanzapine in neurons.

The present study found that olanzapine significantly increased NF-κB levels,
especially the p65 subunit and its phosphorylation level in the neurons. Consistently,
the recent research showed that olanzapine treatment for eight days activated the
NF-κB signaling pathway in the hypothalamus of rats (He et al., 2019). It has been
reported that oxidative stress by exogenously adding hydrogen peroxide resulted in
phosphorylation of p65, and then phosphorylated p65 translocated into the nucleus
to activate the NF-κB downstream signaling (Canty et al., 1999, Takada et al., 2003).
Besides, ROS can stimulate the degradation of the NF-κB inhibitor, IκBα (Takada
et al., 2003), that can bind with p65 and p50 subunits. It is demonstrated that p65
is the direct target of Sirt1. For example, Sirt1 deacetylated the p65 subunit at the
lys310 site, so that the translocation capability of p65 was inhibited (Yeung et al.,
2004, Kauppinen et al., 2013). Therefore, the activation NF-κB signaling pathway
induced by olanzapine may attribute to the accumulation of ROS and decreased
Sirt1 expression.

HDAC2 regulates synaptic plasticity and memory formation (Morris et al., 2013).
We found that olanzapine increased HDAC2 levels in SH-SY5Y neurons.
Previously, clozapine was reported that it elevated the HDAC2 protein level
resulting in decreased mature spine densities in mice, which was attributed to the
binding between the NF-κB transcription factor and HDAC2 promoter (Ibi et al.,
2017). Our present studies confirmed that p65 overexpression induced higher
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expression of HDAC2 in SH-SY5Y cells, which suggested that the HDAC2 was
downstream of the NF-κB signaling pathway. In HDAC2 overexpressed mice, the
memory formation was impaired significantly, and the dendritic spine density was
decreased as well. However, HDAC2 knockout mice showed increased dendritic
spine density inducing the synaptogenesis (Guan et al., 2009). Therefore, the
upregulation of HDAC2 induced by olanzapine in neurons may play an important
role in neurite lesions, leading to cognitive impairments.

BDNF is an important neurotrophic factor for neurite outgrowth (Kellner et al.,
2014). We demonstrated that olanzapine treatment significantly decreased BDNF
levels in SH-SY5Y neurons. Although, the exact mechanism is not very clear, it
was reported that HDAC2 decreased acetylation of histone 3 and 4 near BDNF
promoters to inhibit the expression of BDNF in the brain of mice (Guan et al., 2009).
Therefore, a decreased level of BDNF level in the neurons treated with olanzapine
in the present study may be due to excess HDAC2 bind with histone 3 and histone
4 to reduce the BDNF level. Furthermore, it has been reported that the BDNF level
is correlated with Sirt1 expression and oxidative stress. Schizophrenic patients with
poorer cognitive function showed lower BDNF and Sirt1 levels in plasma (Fang et
al., 2019). In addition, it was confirmed that oxidative stress and a lower level of
BDNF were shown in schizophrenic patients with antipsychotics medication
(Kapczinski et al., 2008, Zhang et al., 2015). Therefore, decreased BDNF level
induced by olanzapine may be associated with the overexpression of HDAC2.

Conclusion
The present study showed that olanzapine induced neuronal lesions with decreased
BDNF expression. It was confirmed that the treatment of olanzapine increased ROS
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production and downregulated Sirt1, which may be involved in the activation of
the downstream NF-κB signaling pathway (Figure 2-6). Furthermore,
overexpression of NF-κB subunit p65 significantly induced HDAC2 protein level
in neurons, suggesting that the upregulation of HDAC2 expression induced by
olanzapine is attributed to the activation of the NF-κB signaling pathway. The
overexpression of HDAC2 in response to olanzapine treatment may contribute to
the genetic regulation of BDNF transcription via histone deacetylation.

Figure 2-6 Proposed mechanism of olanzapine induced neuronal lesions in vitro. Olanzapine
results in oxidative stress and downregulation of Sirt1, which could activate the NF-κB signaling
pathway. The NF-κB transcription factor binds with HDAC2 promoter and upregulates HDAC2
expression. The overexpressed HDAC2 may deacetylated histones near BDNF promoter to
suppress the transcription of the BDNF, which lead to decreased neurite outgrowth.
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CHAPTER 3
Sodium butyrate inhibits HDAC2 activity and attenuates the
olanzapine-induced neuronal deficits

Introduction
Chronic administration of antipsychotic drugs has been reported that it is associated
with cognitive deficits in schizophrenia and caused cognitive impairments in
animal models (Husa et al., 2014, Rosengarten and Quartermain, 2002, Schröder et
al., 2005). It is considered that the cognitive deficit is due to the neuronal lesion
(Huang and Song, 2019, Glausier and Lewis, 2013). The neuronal lesion, as
decreased neurite length, reduced spine density and lower protein expression of
brain-derived neurotrophic factor (BDNF), was found in cortical neurons and
hippocampus of rats treated with different kind of antipsychotic drugs (Hu et al.,
2018, Ibi et al., 2017, Lidow et al., 2001, Ukai et al., 2004, Bai et al., 2003). Also,
previous studies in Chapter 2 showed that olanzapine, one of antipsychotics,
resulted in the reduction in neurite outgrowth and BDNF protein expression in
SH-SY5Y cells. Therefore, targeting BDNF and its upstream signaling molecules
may counteract the neuronal lesion and cognitive impairments induced by
antipsychotic drugs.

It was proved that histone deacetylase (HDAC) inhibitors, such as Trichostatin A
(TSA) and Vorinostat (SAHA), possess the neuroprotective capacity and enhance
cognitive functions (Gaub et al., 2010, Shukla et al., 2016, Guan et al., 2009). Short
chain fatty acids (SCFAs), like butyrate, propionate, and acetate, are considered as
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HDAC inhibitors. SCFAs are products of intestinal microbiota metabolism of
dietary fibers. It was proved that SCFAs or dietary fibers supplementation improved
neurodevelopment and cognition (Lei et al., 2016, Hu et al., 2018, Khan et al., 2015,
Lee et al., 2001). The up-take rate of butyrate to the brain is higher than other
SCFAs (Oldendorf, 1973, Dalile et al., 2019). Administration of sodium butyrate
restored the learning and memory capacities in mouse models of Alzheimer’s
disease (Fischer et al., 2007). Sodium butyrate administration improved the
neuronal degeneration induced by traumatic brain injury in mice (Li et al., 2016).
The supplementation of sodium butyrate relived the depression-like behaviors and
enhanced the lower expression of BDNF in mice exposed to chronic restraint stress
(Han et al., 2014). Moreover, the treatment of sodium butyrate promoted
differentiation of PC12 pheochromocytoma cells and induced increases in dendritic
spine density and branching (Suzuki-Mizushima et al., 2002, Takuma et al., 2014,
Yoo et al., 2011). These results suggest that the sodium butyrate, as an HDAC
inhibitor, may protect neurons from neuronal damages induced by olanzapine.
Furthermore, HDAC2 mediates the impairment of synaptogenesis and cognition.
HDAC2 overexpressed mice showed cognitive deficits, decreased spine density,
and synapse number, while HDAC2 deficient mice showed improvement in
learning capacity and synapse formation (Guan et al., 2009). It was confirmed in
Chapter 2 that olanzapine induced short neurite outgrowth with overexpression of
HDAC2. Although it is reported that butyrate inhibited HDAC2 in the colon tissue
and other peripheral cells (Fellows et al., 2018, Kim et al., 2018, Du et al., 2020),
it is unknown if butyrate can inhibit the deacetylase activity or expression of
HDAC2 to ameliorate the neuronal lesion induced by olanzapine.
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Oxidative stress induces neuronal lesions, such as decreased spine density and
reduced neurite outgrowth (Avila-Costa et al., 1999, Ashabi et al., 2013).
Furthermore, the sirtuin 1 (Sirt1) inhibition led to impairment in neurite outgrowth,
axonogenesis, synaptogenesis, and cognition (Sugino et al., 2010, Li et al., 2013,
Liu et al., 2013, Gao et al., 2010). The interplay between oxidative stress and Sirt1
is shown below. Oxidative stress can result in inhibition of the deacetylase activity
of Sirt1 and stimulate its degradation (Salminen et al., 2013). Sirt1 can stimulate
the antioxidant defense to block oxidative stress (Alcendor et al., 2007). In Chapter
2, it was demonstrated that olanzapine caused oxidative stress and lowered
expression of Sirt1 with severe neurite damages. Previous researches showed that
the administration of sodium butyrate ameliorated the oxidative stress in the lung
tissue of rats models of lung fibrosis (Kabel et al., 2016). Furthermore, sodium
butyrate enhanced the activity of antioxidant enzymes in the frontal cortex and
hippocampus of rats models of mania (Valvassori et al., 2016). The sodium butyrate
promoted the mRNA level of Sirt1 in the lymphoblastoid cell (Rose et al., 2018).
Therefore, sodium butyrate may inhibit oxidative stress and upregulate Sirt1 to
improve neuronal lesions.

It is reported that the NF-κB signaling pathway can be activated by oxidative stress
and lower expression of Sirt1 (Schreck et al., 1992, Van den Berg et al., 2001,
Salminen et al., 2008b). The NF-κB signaling pathway involved in decreased spine
density and impaired neurite outgrowth (Meissner et al., 2015, Gutierrez et al.,
2008). Translocated NF-κB inside the nucleus binds with the HDAC2 promoter and
results in a higher expression of HDAC2 (Ibi et al., 2017). Consistently, results in
Chapter 2 proved that the activation NF-κB signaling pathway and upregulation of
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HDAC2 were induced by olanzapine in SH-SY5Y cells with neurite damages.
Previous researches showed that sodium butyrate inhibited the NF-κB signaling
pathway via a block of phosphorylation of IκBα in colorectal adenocarcinoma cells
(COLO 205 cell line), murine monocyte/macrophage-like cells (RAW264.7 cell
line) and mouse peritoneal macrophages (Lee et al., 2017). Butyrate downregulated
NF-κB transcriptional activity in hippocampus slice exposed to LPS and inhibited
neuroinflammation in primary microglia (Huuskonen et al., 2004). Therefore,
SCFAs can inhibit the transcription mediated by NF-κB and suppress
neuroinflammation in cancer or immune cells. However, it is still unknown if
sodium butyrate could inhibit the NF-κB signaling pathway in neurons and
ameliorate the olanzapine-induced neurite lesions.

In the present study, we aimed to examine if sodium butyrate could prevent
neuronal damages induced by olanzapine. Also, the underlying mechanism will be
investigated by examination of the level of oxidative stress marker — ROS and
Sirt1, the NF-κB signaling pathway, and enzyme activity and expression of HDAC2
by flow cytometry, immunofluorescence, western blot, and deacetylase activity
assay kits.

Materials and methods
1. Cell culture and treatments
The undifferentiated neuroblastoma cell line-SH-SY5Y was established in Prof.
Huang’s lab, the University of Wollongong, Australia. SH-SY5Y cells were grown
in Dulbecco’s Modified Eagle Medium mixed with F12 supplementation
(DMEM/F12, Life Technologies) with 10% heat-inactivated fetal bovine serum
(FBS, Gibco), and 1% penicillin-streptomycin (P/S, Thermofisher) at 37°C in 95%
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air/5% CO2. In order to stimulate differentiation, cells were seeded in the plate,
which has been coated with MaxGel™ ECM (1:100, E0282, Sigma Aldrich) diluted
in fresh medium for 1hour incubation. On the following day, the medium needed to
be replaced by 1% FBS in DMEM/F12 with 10μM retinoic acid (RA, R2625, Sigma
Aldrich) for 24 hours.

According to the method published by Hilgenberg and Smith (2007), cortical
neurons were harvested from the postnatal day 0~3 of C57BL/6J mice, which has
been approved by the Animal Ethics Committee, University of Wollongong,
Australia, and complied with the Australian Code of Practice for the Care and Use
of Animals for Scientific Purposes. Briefly, the frontal cortex was dissected and cut
into small pieces in dissection solution (Appendix). After incubation with the 5ml
enzyme solution (Appendix) at 37°C incubator for 30 minutes, the cortical neuron
was resuspended in Neurobasal™ medium (21103049, Gibco) with B-27™
supplement (17504044, Gibco), 1% P/S and 0.1 M glucose (G-8270, Sigma
Aldrich). The cortical neuron was seeded in the glass coverslip, which had been
coated with poly-D-lysine (p6407, Sigma Aldrich) at 4°C overnight. The
5-fluoro-2′-deoxyuridine (F0503, Sigma Aldrich) was added to the culture medium
to inhibit the growth of glial cells at a final concentration of 10μM after 24 hours
of culture.

The differentiated SH-SY5Y cell or the primary cortical neuron was treated with
100μM olanzapine (11937, Cayman Chemical) for 24 hours or 3 hours with or
without pre-treatment of sodium butyrate (5 or 10μM) (B5887, Sigma Aldrich) for
30 minutes. SH-SH5Y cells were exposed to a range of sodium butyrate from 0 to
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5mM for 24 hours to choose the appropriate concentration for neuroprotection. All
the reagent was dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich).

2. HDAC2 activity assay
FLUOR DE LYS®-Green HDAC2 fluorometric drug discovery assay kit
(BML-AK512-0001, Enzo Life Sciences) was used for the detection of
recombinant HDAC2 activity exposed to a range of different concentrations of
sodium butyrate. According to the manufacturer’s protocol, 15μl recombinant
HDAC2 (1ng) was mixed with 25μl FLUOR DE LYS®-Green substrate (20μM)
and 10μl different concentrations of sodium butyrate at final concentrations of 1μM,
10μM, 50μM, 100μM, 1mM, 2mM, and 10mM in the wells of the corresponding
microplate for 1 hour incubation at room temperature. Then 50μl FLUOR DE
LYS®-Green developer containing 2μM TSA was added into each well to stop the
reaction between the recombinant HDAC2 and substrates. The plate was shaken at
room temperature for 15 minutes, and the fluorescence was determined by
FlexStation 3 multi-mode microplate reader (Molecular Devices) with excitation
wavelength at 485nm and emission wavelength at 528nm. The HDAC2 activity
was calculated as the percentage of fluorescence intensity of treated groups
compared with that of the control group.

The inhibition of cell-derived HDAC2 deacetylase activity by sodium butyrate was
detected

based

on

the

previous

publication

(Reddy

et

al.,

2018).

Immunoprecipitation was carried out to isolate HDAC2 protein from SH-SY5Y
cells treated with 10μM sodium butyrate for 24 hours. Briefly, after the treatment
of sodium butyrate, SH-SY5Y cells were lysed with the homogenous buffer,
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comprising of 0.5mM β-glycerophosphate (G-9422, Sigma Aldrich), 1mM PMSF
(P7626, Sigma Aldrich), and protease inhibitor cocktail (PIC, P-8340, Sigma
Aldrich). After protein concentration for each sample was determined by DC
protein assay (5000116, Bio-rad) and detected by SpectraMax Plus384 absorbance
microplate reader at the wavelength of 750nm, 500μg total protein was dissolved
in 200μl homogenous buffer and mixed with 1μl HDAC2 antibody (3F3) (1:200,
#5113, Cell Signaling Technologies) at 4°C overnight. On the following day, the
centrifuge tube containing 50μl Dynabeads™ Protein A (10002D, Thermofisher)
was put on the magnet and washed with the homogenous buffer. The 200μl cell
lysate with HDAC2 antibody was transferred into the tube containing magnetic
beads and incubated with rotation at room temperature for 20 minutes. After
washed

5

times

with

homogenous

buffer,

the

100μl

10μM

substrate--Boc-Lys(Ac)-AMC (29682, Cayman Chemical) was added into the tube
containing bead-antibody-HDAC2 complex. After 30 minutes of incubation at
room temperature, 50μl of the deacetylated substrate was added into wells of the
corresponding microplate with 50μl developer containing 100 μM trypsin (T1426,
Sigma Aldrich) and 100 nM TSA (89730, Cayman Chemical). Then the plate was
incubated at room temperature for more than 15 minutes. To confirm that
olanzapine had no impact on HDAC2 activity, 15μl recombinant HDAC2 (1ng),
25μl 10μM substrate, and 10μl olanzapine at a final concentration of 100μM were
mixed and incubated for 30 minutes at room temperature. Then the 50μl developer
was added into each well of corresponding microplates, and the plate was incubated
for more than 15 minutes. The fluorescence was determined with the FlexStation 3
multi-mode microplate reader at the excitation wavelength at 360nm and emission
wavelength at 460nm. The HDAC2 activity was shown as the percentage of
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fluorescence intensity of samples treated with sodium butyrate relative to that of
the control group.

3. Measurement of neurite outgrowth and spine density
For differentiated SH-SY5Y cells, the neurite outgrowth was monitored via the
real-time IncucyteZoom system and analysed by Neurotracker software (Essen
BioScience). At 7 days in vitro (DIV7), the primary cortical neuron was treated with
olanzapine for 24 hours with or without pre-treatment of sodium butyrate for 30
minutes. After washed one time with phosphate-buffered saline (PBS), cortical
neurons were fixed with 4% formaldehyde for 15 minutes. Then cells were washed
with PBS two times and were permeablized with 0.3% Triton X-100 for 10 minutes.
After cells were blocked with 5% normal donkey serum in 0.3% Triton X-100 for
1 hour at room temperature, the cell was incubated with MAP2 antibody (1:800,
M4403, Sigma Aldrich) dissolved in 1% normal donkey serum at 4°C overnight.
The next day, the cell was incubated with secondary antibody Alexa Fluor 488conjugated donkey anti-mouse IgG (1:400, A-21202, Invitrogen) in 1% normal
donkey serum for 1 hour at room temperature. The glass coverslip was mounted
with ProLong™ Diamond Antifade Mountant (p36961, Thermofisher) and
visualized by using a 40X oil immersion objective on DMI6500B confocal
microscope (Leica). The ImageJ software (NIH) was used to analyse the total
neurite length.

Similarly, after cultured for 21 days in vitro (DIV21) and treated with olanzapine
and sodium butyrate, the primary cortical neuron was fixed with 4% formaldehyde
for 15 minutes before incubation with 0.3% Triton X-100 for 5 minutes. Then the
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cell was stained with Phalloidin-iFluorTM 594 Conjugate (1:1000, 20553, Cayman
Chemical) dissolved in 1% bovine serum albumin (BSA) for 90 minutes at room
temperature. After rinsed for 3 times, the glass coverslip was mounted with
ProLong™ Diamond Antifade Mountant and visualized by using a 63X oil
immersion objective on DMI6500B confocal microscope. The spine density was
calculated by using the ImageJ software. Dendritic segments that were not
overlapped with other branches were picked 50μm away from the soma randomly
and. More than 4 dendritic segments per cell with a total neurite length of more
than 80μm were measured in 20 neurons per group.

4. Measurement of reactive oxygen species (ROS) production
SH-SY5Y cells were treated with olanzapine with or without pre-treatment of
sodium butyrate for 24 hours. The cellular and mitochondrial ROS levels were
determined by staining with 10μM 2’,7’-Dichlorofluorescein diacetate (DCFDA,
20656, Cayman Chemical) and 5μM Mitosox (M36008, Thermofisher) for 30
minutes and 15 minutes, respectively. The fluorescence intensity of the stained cell
was detected with the Accuri C6 flow cytometer (BD Bioscience) and visualized
with a 20X DMI8 Fluorescent Microscope (Leica).

5. Real-time polymerase chain reaction (RT-PCR)
The primary cortical neuron (DIV7) were treated with olanzapine with or without
sodium butyrate for 3 hours. Messenger RNA (mRNA) was extracted with the
Aurum™ Total RNA Mini Kit (7326820, Bio-Rad). According to the
manufacturer’s protocol, cortical neurons were lysed with the lysis buffer
containing 1% β-mercaptoethanol (M6250, Sigma Aldrich) and then mixed with
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70% ethanol. Then the mixture was added into RNA binding columns, which were
inside of 2ml capless wash tubes. After washed and centrifuged at 13000rcf for 30
seconds, the 5μl reconstituted DNase I diluted in 80μl DNase dilution buffer was
added in the membrane of each column for 15 minutes incubation. After washed 2
times, the RNA binding column was transferred into a new 1.5ml capped centrifuge
tube, and the 40μl elution buffer was added into each tube. The total mRNA was
received after the column was incubated with elution buffer for 1 minute and
centrifuged.

The total mRNA concentration was determined with NanoDrop™ 2000
Spectrophotometers (Thermofisher). The reverse transcription of 500ng mRNA
sample was performed by the High-Capacity cDNA Reverse Transcription Kit
(4368813, Applied Biosystems™). According to the manufacturer’s protocol, the
20µl reaction system is consisted with 2µl 10X RT buffer, 0.8 µl 25X dNTP mix
(100mM), 2µl 10X RT random primers, 1µl MultiScribeTM reverse transcriptase,
4.2µl nuclease-free H2O and 10µl mRNA sample in 1.5ml centrifuge tube. The tube
was placed at 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes and
was stored at 4°C.

PCR amplification was performed by using the SensiFASTTM SYBR No-ROX kit
(BIO-98005, Bioline) and detected with QuantStudio™ 5 Real-Time PCR System
(Thermo Fisher Scientific). Following the manufacturer’s protocol, for each well
in a corresponding microplate, 2µl synthesized DNA template was mixed with 1µl
forward primer, 1µl reverse primer, 6µl nuclease-free H2O and 10µl SensiFASTTM
SYBR No-ROX reagent. The cycling condition was set as 95°C for 2 minutes for
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polymerase activation, and 40 repeatable cycles were adjusted as 95°C for 5
seconds (denaturation), 60°C for 10 seconds (annealing), and 72°C for 10 seconds
(extension). The mRNA expression level of target genes was calculated by using
the 2−ΔΔCt method, in which the ΔΔCt is the value of ΔCt of the control group
subtracted by that of treatment groups. All mRNA levels (Table 3-1) were
normalized to that of Glyceraldehyde 3- phosphate dehydrogenase (GAPDH).

6. Western blot
After the SH-SY5Y cell was treated with olanzapine with or without pre-treatment
of sodium butyrate for 24 hours, the cell pallet was lyzed by using the homogenous
buffer and left on the ice for 1 hour. After the lysate was centrifuged at 5000rpm
for 5 minutes at 4°C, the supernatant was isolated and stored at -80°C. Following
the manufacturer’s protocol, DC protein assay (500-0116, Bio-rad) was used for
the determination of the protein concentration for each sample. The fluorescence
was detected by using the SpectraMax Plus384 absorbance microplate reader at the
wavelength of 750nm. Loading samples were comprised of the laemmli buffer and
12μg protein. After heated at 95°C for 5 minutes, the sample was loaded into the
10% SDS-PAGE gels (5678025, Bio-rad). Following the gel electrophoresis for
Table 3-1 The forward primer and reverse primer of target genes
Gene
GAPDH
BDNF

MAP2
PSD-95
Synaptophysin

Primer Sequence
Forward primer

5’-TGA-AGC-AGG-CAT-CTG-AGG-G-3’

Reverse primer

5’-CGA-AGG-TGG-AAG-AGT-GGG-AG-3’

Forward primer

5’-GGG-TCA-CAG-CGG-CAG-ATA-AA-3’

Reverse primer

5’-GCC-TTT-GGA-TAC-CGG-GAC-TT-3’

Forward primer

5’-ATG-AAG-GAA-AGG-CAC-CAC-AC-3’

Reverse primer

5’-AAT-AGG-TGC-CCT-GTG-ACC-TG-3’

Forward primer
Reverse primer

5’-GGT-GAC-GAC-CCA-TCC-ATC-TTT-ATC-3’
5’-CGG-ACA-TCC-ACT-TCA-TTG-ACA-AAC-3’

Forward primer

5’-GAA-CAA-GTA-CCG-AGA-GAA-CAA-CAA-3’

Reverse primer

5’-GGT-CAG-TGG-CCA-TCT-TCA-CA-3’
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separation at 120 voltage for 80 minutes at room temperature, the polypeptide was
transferred into polyvinylidene difluoride (PVDF) membranes (1620177, Bio-rad)
at 100 voltage for 60 minutes at 4°C. The 5% skim milk in TBST buffer (150 mM
NaCl, 10 mM Tris, and 0.075% Tween‐20, pH 7.5) was used to block the membrane
for 1 hour at room temperature. Then the membrane was incubated with the primary
antibody, as HDAC2 (3F3), NF-κB p65 (D14E12), NF-κB1 p105/p50 (D4P4D),
Sirt1 (1:1000, #5113, #8242, #24961, Cell Signaling Technologies), anti-β-actin
(1:3000, Millipore) and BDNF (1:200, SC-546, Santa Cruz) dissolved in 1% skim
milk in TBST at 4°C overnight. After washed 3 times for 5 minutes, the membrane
was incubated with the secondary antibody as goat anti-mouse (1:3000, 31460,
Invitrogen) and goat anti-rabbit (1:3000, AP308P, Millipore) antibody for 1 hour at
room temperature. The band was visualized with the Enhanced Chemiluminescence
(ECL) western blotting detection reagent (GE Healthcare) under the Amersham Gel
Imager (GE Healthcare).

7. Statistics
GraphPad Prism 5 (GraphPad Software) was used for analysis. The one-way
analysis of variance (ANOVA) following the Turkey’s post hoc test was used for
comparisons between multiple groups except for sholl analysis, whereas the
unpaired t-test was used for comparisons between two groups. For sholl analysis,
the two-way repeated-measures ANOVA followed by Turkey’s post hoc test was
used. The data were shown as mean ± SEM, and p<0.05 was recognized as a
significant difference.
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Results
1. Sodium butyrate prevents neurite deficits induced by olanzapine in
SH-SY5Y cells
Butyrate is the most uptake SCFAs to the brain and previously reported to increase
neurite length in PC12 pheochromocytoma cell (Suzuki-Mizushima et al., 2002,
Oldendorf, 1973, Dalile et al., 2019). Here, we investigated that if the sodium
butyrate could improve the neurite outgrowth impairment induced by olanzapine in
SH-SY5Y cells. Firstly, the neurite length of SH-SY5Y cells treated with sodium
butyrate (0 to 5mM) was determined by the IncucyteZoom system. The result
showed that the sodium butyrate (0 to 100μM) did not significantly affect the
neurite length, while higher concentrations over 500μM induced a significant
decrease in neurite outgrowth (Figure 3-1A). It is reported that the concentration
of butyrate in human cerebrospinal fluid (CSF) is at the micromolar level (Wishart
et al., 2018). Besides, it is confirmed that sodium butyrate at lower concentrations
did not affect neurite length. Moreover, previously it is found that butyrate at 10μM
inhibited the apoptosis induced by 6-hydroxydopamine (6-OHDA) in SH-SY5Y
cells (Funakohi-Tago et al., 2018). Therefore, the clinically feasible concentration,
as 5μM and 10μM, of sodium butyrate was used to examine the neurite length in
the following experiments. It is found that co-administration of sodium butyrate at
10μM and olanzapine significantly increased neurite length compared with the
olanzapine group, while sodium butyrate at 5μM did not ameliorate the olanzapineinduced neurite lesions (Figure 3-1B). Furthermore, live-cell images from the
IncucyteZoom system showed that the SH-SY5Y cell treated with 10μM sodium
butyrate and 100μM olanzapine had longer neurites compared with that of the
olanzapine treatment only group (Figure 3-1C).
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Figure 3-1 Sodium butyrate (Buty) improves the neurite deficit induced by olanzapine
(Olan) in SH-SY5Y cells. A) The change of neurite outgrowth of SH-SY5Y cells exposed to
different concentrations of sodium butyrate for 24 hours. N = 6. The data was shown as
mean ± SEM and analysed by one-way ANOVA. ***p < 0.001, **p < 0.001, versus the control
group. B) The change of neurite length of SH-SY5Y cells with pre-treatment of sodium butyrate
(5, 10µM) and the treatment of olanzapine (100µM) for 24 hours. The data was shown as
mean ± SEM and analysed by one-way ANOVA. N = 4. ***p < 0.001, versus the control group,
##p < 0.01, versus with the olanzapine group. C) Representative images of morphology of
SH-SY5Y cells treated with 100μM olanzapine with or without 10μM sodium butyrate for 24
hours. Scale bar = 150µm.
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2. Sodium butyrate prevents decreased neurite length and spine density
induced by olanzapine in primary cortical neurons
The primary cortical neuron, as a physiological model of neurons (Nolan, 2007),
was used to examine the protective effect of sodium butyrate on the synaptogenesis.
After cortical neurons were cultured for 7 days, cells were treated with 10μM
sodium butyrate prior to 100μM olanzapine for 24 hours. After stained with the
MAP2 antibody, the neurite outgrowth was visualized and analysed. The neurite
outgrowth of cortical neurons treated with olanzapine was shorter compared with
the control group, whereas the pre-treatment with sodium butyrate can reverse that
lesion (Figure 3-2A). The quantification of the total dendrite length of cortical
neurons showed that olanzapine significantly decreased the total neurite length per
cell compared with the control group (Figure 3-2B). However, the pre-treatment
with sodium butyrate significantly increased the neurite length per cell from 300μm
to 432μm approximately compared with olanzapine treatment alone group. Besides,
the sholl analysis was used to examine the morphology of dendrites (Sholl, 1953).
A series of concentric circles were created from the soma of cortical neurons every
5μm, and the intersection between dendrites and circles was counted. The result
showed a significant reduction of intersections in cortical neurons treated with
olanzapine when compared with the control group (Figure 3-2C). However, the
pre-treatment with sodium butyrate significantly increased the number of
intersections in primary cortical neurons compared with the olanzapine treatment
only group (Figure 3-2D). It indicates that sodium butyrate can prevent the deficit
in neurite outgrowth (complexity of dendritic tree) induced by olanzapine.

The effects of olanzapine and sodium butyrate on spine density were further
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Figure 3-2 Sodium butyrate (Buty) reverses the decreased neurite length and spine density
induced by olanzapine (Olan) in primary cortical neurons. A) Representative images of mouse
cortical neurons after pre-treatement of 10µM sodium butyrate and treatment of 100µM olanzapine for
24 hours. Scale bar = 20µm. B) Quantification of the average of total neurite length per cortical neuron
after treatment with sodium butyrate and olanzapine for 24 hours. Data was shown as mean ± SEM
and analysed by one-way ANOVA. 19≤ N ≤29. ***p < 0.001, versus the control group, ## p <0.01,
versus the olanzapine group. Sholl analysis of cortical neurons after treatment with C) 100µM
olanzapine D) with or without pre-treatment with 10µM sodium butyrate for 24 hours. The data was
shown as mean ± SEM and analysed by two-way ANOVA. 19≤ N ≤29. ***p < 0.001, versus the
control group, ##p < 0.01, versus the olanzapine group. E) Representative images of dendrite segments
of DIV21 cortical neurons with treatment of olanzapine and sodium butyrate for 24 hours. Scale
bar = 5μm. F) The quantification of basal spine density in primary cortical neurons after treatment with
olanzapine with or without pre-treatment of sodium butyrate for 24 hours. Data were shown as
mean ± SEM and analysed by one-way ANOVA. **p < 0.01, versus the control group, ###p < 0.001,
versus the olanzapine group. N = 20.
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examined in DIV21 primary cortical neurons stained with phalloidin. The result
revealed that sodium butyrate significantly increased the spine density (mean: 0.76
± 0.04 spines/μm) of primary cortical neurons compared with the control group
(mean: 0.60 ± 0.02 spines/μm). Furthermore, olanzapine markedly decreased the
spine density (mean: 0.46 ± 0.03 spines/μm) compared with the control group,
while the pre-treatment of sodium butyrate significantly increased the spine density
(mean: 0.70 ± 0.03 spines/μm) compared with olanzapine treatment alone group
(Figure 3-2E, F). These results suggest the sodium butyrate protects the cortical
neurons from the synaptogenesis impairment (neurite outgrowth and spine density)
induced by olanzapine.

3. Sodium butyrate reverses the lower expression of BDNF in neurons
induced by olanzapine
Next, the level of neurotrophic factor and synaptic proteins, BDNF, MAP2,
synaptophysin, and PSD95, were examined in neurons in response to olanzapine
and sodium butyrate. Olanzapine resulted in a significantly lower mRNA level of
BDNF in primary cortical neurons compared with the control group, whereas the
pre-treatment of sodium butyrate markedly increased mRNA level of BDNF
compared with olanzapine treatment only group (Figure 3-3A). However, sodium
butyrate and olanzapine did not impact the mRNA level of MAP2, Synaptophysin,
and PSD95. At the protein level, the result of western blot showed that sodium
butyrate inverted the decreased BDNF protein level induced by olanzapine in
SH-SY5Y cells (Figure 3-3B, C). These observations suggest that the sodium
butyrate reverses the neurotrophic factor BDNF deficit induced by olanzapine.
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Figure 3-3 Sodium butyrate (Buty) reverses the downregulated mRNA level and protein level
of BDNF induced by olanzapine (Olan). A) The change of mRNA level of BDNF, MAP2, PSD95
and synaptophysin in primary cortical neurons with treatment of sodium butyrate (10μM) and
olanzapine (100μM) for 3 hours. N = 4. Data was shown as mean ± SEM and analysed by
one-way ANOVA. **p < 0.01, versus the control group, ##p < 0.01, versus the olanzapine group.
B) The quantification of protein level of BDNF in SH-SY5Y cells treated with sodium butyrate
and olanzapine for 24 hours. N = 4. Data was shown as mean ± SEM and analysed by one-way
ANOVA. **p < 0.01, versus the control group, #p < 0.05, versus the olanzapine group. C)
Representative images of western blot of BDNF protein.

4. Sodium butyrate inhibits HDAC2 enzyme activity
HDAC2 is reported to inhibit BDNF expression (Guan et al., 2009). Following
sodium butyrate increased the BDNF level in neurons exposed to olanzapine, next,
we assessed the ability of sodium butyrate in inhibition of HDAC2 enzyme activity
by using the recombinant HDAC2 protein and SH-SY5Y cells-derived HDAC2
protein respectively. Different concentrations of sodium butyrate ranged from 1μM
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to 10mM were react with recombinant HDAC2 protein. The activity of recombinant
HDAC2 was significantly inhibited by sodium butyrate in a dose-dependent
manner (Figure 3-4A). Previous results confirmed that 10μM sodium butyrate
significantly ameliorated the olanzapine-induced neurite lesion in SH-SY5Y cells
compared with the control group (Figure 3-1B). Therefore, whether 10μM sodium
butyrate could inhibit HDAC2 deacetylase activity in SH-SY5Y cells was
examined here. The HDAC2 protein derived from sodium butyrate-treated
SH-SY5Y cells was

separated from the total cell lysate by using

immunoprecipitation, followed by incubation with substrates. The result showed

Figure 3-4 Sodium butyrate (Buty), but not olanzapine (Olan), inhibits the HDAC2
deacetylase activity. A) Dose response of sodium butyrate on deacetylase activity of recombinant
HDAC2 protein. The data was shown as mean ± SEM and analysed by one-way ANOVA. N = 3.
***p < 0.001, versus the control group. B) The change of deacetylase activity of HDAC2 in
SH-SY5Y cells treated with 10μM sodium butyrate for 24 hours. Data was shown as mean ± SEM
and analysed by unpaired t-test. N = 7. *p < 0.05, versus the control group. C) The change of
enzyme activity of recombinant HDAC2 reacted with olanzapine at 100μM. Data was shown as
mean ± SEM and analysed by unpaired t-test.
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that the HDAC2 enzyme activity in SH-SY5Y cells was significantly blocked in
the sodium butyrate group compared with the control group (Figure 3-4B).
Olanzapine did not affect the HDAC2 deacetylase activity (Figure 3-4C), although
olanzapine is found to increase the HDAC2 protein level in SH-SY5Y cells
(Chapter 2). These results suggest that sodium butyrate is an HDAC2 enzyme
inhibitor in neurons.

5. Sodium butyrate does not reverse olanzapine’s effects on the ROS level
and Sirt1 expression in SH-SY5Y cells
It has been previously shown that the olanzapine induced higher ROS level and
lower expression of Sirt1 protein (Chapter 2). To examine whether sodium
butyrate could affect the ROS level, DCFDA and Mitosox staining were used to
evaluate the intracellular and mitochondrial ROS in SH-SY5Y cells. Sodium
butyrate did not alter the fluorescence intensity of DCFDA and Mitosox in
SH-SY5Y cells, suggesting sodium butyrate did not affect ROS production
(Figure 3-5A~D). Furthermore, although olanzapine increased the fluorescence
intensity of DCFDA and Mitosox in SH-SY5Y cells, the pre-treatment of sodium
butyrate did not attenuate olanzapine’s effects. In addition, sodium butyrate alone
treatment did not influence the Sirt1 protein level (Figure 3-5E, F). The coadministration of sodium butyrate and olanzapine did not restore the reduction of
Sirt1 expression induced by olanzapine. The result indicates that sodium butyrate
can not prevent alteration of ROS production and the Sirt1 level induced by
olanzapine in neurons.
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Figure 3-5 Sodium butyrate (Buty) does not ameliorate the ROS accumulation and the decreased
Sirt1 expression induced by olanzapine in SH-SY5Y cells. The quantification of fluorescence
intensity of SH-SY5Y cells stained with A) DCFDA (FITC) and B) Mitosox (PE) after treatment with
olanzapine and sodium butyrate for 24 hours determined by flow cytometry. The corresponding
histogram of flow cytometry was shown. Black line, the control group, red line, the olanzapine group,
yellow line, the combination of sodium butyrate and olanzapine group. Data was shown as
mean ± SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, **p < 0.01, versus the control
group. Representative images of SH-SY5Y cells stained with C) DCFDA and D) Mitosox imaged by
the fluorescence microscopy. Scale bar = 100μm. E) The quantification of Sirt1 protein level in
SH-SY5Y cells exposed to sodium butyrate and olanzapine for 24 hours. Data were shown as mean ±
SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, compared with the control group. F) The
representative image of the western blot of Sirt1 protein.
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6. Sodium butyrate does not prevent the alteration of p65, p50, and HDAC2
induced by olanzapine in SH-SY5Y cells
The activation of the NF-κB pathway and the upregulation of its downstream
protein — HDAC2 were observed in SH-SY5Y cells after treatment with
olanzapine (Chapter 2). Here we examined that if sodium butyrate could prevent
olanzapine’s effect on NF-κB and HDAC2 levels. The sodium butyrate alone did
not significantly change the NF-κB subunits, p65, and p50 (Figure 3-6A~D). The
pre-treatment of sodium butyrate did not prevent the effect of increased p65
induced by olanzapine (Figure 3-6A). Besides, the sodium butyrate did not affect
the HDAC2 protein level in SH-SY5Y cells (Figure 3-6E, F). Although olanzapine
significantly increased the HDAC2 protein level, there was no significant
difference in HDAC2 protein level between the group of sodium butyrate and
olanzapine combination compared with the olanzapine alone group. Therefore,
these results indicate that sodium butyrate can not prevent olanzapine’s effects on
activation of the NF-κB pathway and upregulation of HDAC2 expression.
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Figure 3-6 Sodium butyrate (Buty) cannot reverse the overexpression of p65 and HDAC2 in
SH-SY5Y cells. Quantification of the protein level of A) p65, C) p50, and E) HDAC2 in
SH-SY5Y cells after treatment with olanzapine and sodium butyrate for 24 hours. Data was shown
as mean ± SEM and analysed by one-way ANOVA. N = 4. *p < 0.05, versus the control group.
The representative image of western blot of B) p65, D) p50 and F) HDAC2.

Discussion
In this chapter, it is found that sodium butyrate prevented the neurite outgrowth
impaired by olanzapine both in the neuroblastoma cell line (SH-SY5Y cells) and
primary cortical neurons. Besides, the reduced total neurite length and dendritic
spine density induced by olanzapine were restored by sodium butyrate as well.
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Importantly, sodium butyrate reinstated neurotrophic factor, BDNF level in neurons
exposed to olanzapine. With HDAC2 enzyme activity assay, sodium butyrate
significantly inhibited the deacetylase activity of recombinant HDAC2 and
SH-SY5Y cell-derived HDAC2 protein. However, sodium butyrate did not
ameliorate olanzapine-induced oxidative stress, lower Sirt1 level, activation of the
NF-κB signaling pathway, and higher HDAC2 protein level caused by olanzapine.
Therefore, sodium butyrate may improve the impairment of synaptogenesis
induced by olanzapine via inhibition of HDAC2 enzyme activity to increase BDNF
expression, but not via regulation of oxidative stress and Sirt1expression, and
modulation of the NF-κB signaling pathway and HDAC2 expression.

In SH-SY5Y neuronal cells and primary cortical neurons, sodium butyrate
prevented olanzapine’s deleterious effects on neurite length, neurite morphology,
and spine density. Our results are supported by previous in vitro and in vivo study
in which sodium butyrate promotes the neurite outgrowth. For example, it was
reported that sodium butyrate promoted the neurite outgrowth and differentiation
in PC12 cells derived from a pheochromocytoma of the rat adrenal medulla
(Uittenbogaard et al., 2018, Suzuki-Mizushima et al., 2002). Moreover, chronic
treatment of sodium butyrate significantly increased spine density in the
hippocampal region of mice (Takuma et al., 2014). Moreover, the butyrate
administration enhanced the number of tertiary dendrites of neurons in the brain
region of the dentate gyrus in mice (Yoo et al., 2011). Previous animal and human
studies reported that antipsychotics induced the loss in the cortical grey matter
volume and reduced the number of the synaptic spine in cortical neurons (Vita et
al., 2015, Ibi et al., 2017, Koini et al., 2018). The loss of synaptic spine attribute to
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cognitive decline in antipsychotic treated patients (Taoufik et al., 2018, Husa et al.,
2014). Our findings in neurons showed that sodium butyrate improved the
impairment of synaptogenesis induced by olanzapine, suggesting that sodium
butyrate may prevent antipsychotics-induce cognitive deficits. In addition, sodium
butyrate supplementation has been safely used in a clinical trial in obese individuals
(Cleophas et al., 2019). Therefore, sodium butyrate may have the potential for
clinical use to prevent antipsychotics-induced deficits in synaptogenesis and
cognition.
Previously, the long-term treatment of sodium butyrate counteracted with the
decreased BDNF expression in the hippocampus of mice induced by chronic
restraint stress (Han et al., 2014). Here, we found that sodium butyrate increased
the lower BDNF expression induced by olanzapine in neurons. It is known that
BDNF expression can be suppressed by HDAC2 due to the deacetylation of histone
3 or 4 near the BDNF promoter (Guan et al., 2009). We found that olanzapine
increased HDAC2 protein levels, which may be involved in the inhibition of BDNF
expression. In the present study, sodium butyrate did not inhibit the increased
HDAC2 protein level induced by olanzapine. However, the enzyme activity assay
showed that sodium butyrate inhibited the deacetylase activity of both the
recombinant HDAC2 and SH-SY5Y cells-derived HDAC2 protein. Therefore,
sodium butyrate in the amelioration of decreased BDNF expression induced by
olanzapine may be due to its effect on the inhibition of HDAC2 enzyme activity,
but not HDAC2 protein level. Furthermore, HDAC2 inhibition has been shown to
rescue impaired synaptogenesis and cognitive deficits. For example, the significant
increase in spine density, synapse number, and synaptic plasticity was observed in
the hippocampus of HDAC2 knockout mice (Guan et al., 2009). Also, the
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HDAC2-deficient mice showed improved learning behaviors and working memory
compared with the wild type mice. In this study, we found that sodium butyrate
servers as an HDAC2 inhibitor in the neurons, which may contribute to the
amelioration of neurite lesions induced by olanzapine.

Our results demonstrated that sodium butyrate at 10μM did not impact the oxidative
stress in SH-SY5Y neuronal cells. However, previous researches show the dual
effect of sodium butyrate on oxidative stress. For example, in NRK-52E cells, a rat
kidney proximal tubular epithelial cell line, the sodium butyrate (0.1mM ~ 1mM)
increased the level of superoxide dismutase (enzyme against oxidative stress) to
prevent the oxidative stress induced by high glucose (Du et al., 2020). Besides,
when HepG2 cells (liver cancer cells) were exposed to 800μM hydrogen peroxide,
the pre-treatment of sodium butyrate (0.2mM ~ 0.4mM) relieved the ROS
accumulation via the enhancement of antioxidants (Xing et al., 2016). Furthermore,
higher doses of sodium butyrate at 4mM induced ROS production in
hepatocarcinoma cells (Pant et al., 2017b, Pant et al., 2017a). These findings
suggest that the effect of sodium butyrate on oxidative stress may depend on the
concentration of sodium butyrate and cell types.

Oxidative stress inhibits the Sirt1 expression and activity; also, the overexpression
of Sirt1 induces the production of antioxidants (Yeung et al., 2004, He et al., 2019,
Salminen et al., 2013). In the present study, sodium butyrate at 10μM did not alter
the Sirt1 level in the SH-SY5Y neuronal cells. This finding is consistent with the
previous research in which sodium butyrate at 100μM did not affect the gene
expression of Sirt1 in the lymphoblastoid cells (Rose et al., 2018). However, it is
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found that higher doses of sodium butyrate affected the Sirt1 level. For example,
Rose’s team found that sodium butyrate at 1mM increased Sirt1 expression in the
lymphoblastoid cells. However, sodium butyrate (more than 0.5mM) inhibited the
Sirt1 expression in lymphoma cells (Das et al., 2015). These findings indicate that
the sodium butyrate may affect Sirt1 expression at higher doses, but no effects at
lower doses. In the present study, pre-treatment of sodium butyrate at 10μM did not
counteract the decreased Sirt1 expression induced by olanzapine along with
oxidative stress. These findings suggest that the effect of sodium butyrate at higher
doses to prevent the decreased Sirt1 expression and oxidative stress induced by
olanzapine requires further examination.

It is confirmed that the butyrate exerts anti-inflammation properties via inhibition
of NF-κB activation (Hamer et al., 2008, Segain et al., 2000). Also, the similar
effect was reported that higher doses of sodium butyrate (more than 0.1mM)
suppressed the phosphorylation of IκBα (NF-κB inhibitor) in colon carcinoma cells,
inducing inhibition of NF-κB signaling pathway (Lee et al., 2017). In the present
study, activation of the NF-κB signaling pathway cannot be suppressed by sodium
butyrate in neurons, which may be due to the lower concentration of sodium
butyrate and different cell types. The activation of the NF-κB signaling pathway is
regulated by oxidative stress and Sirt1 inhibition (Canty et al., 1999, Takada et al.,
2003, Kauppinen et al., 2013, Yeung et al., 2004). Therefore, sodium butyrate
cannot prevent the activation of the NF-κB signaling pathway may be due to
unchanged oxidative stress and Sirt1 expression in response to sodium butyrate at
low concentration.
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Our results suggest that sodium butyrate can serve as an HDAC2 inhibitor in a
dose-dependent manner ranged from 1µM to 10mM. It is consistent with findings
of previous studies that the half-inhibitory concentration (IC50) of sodium butyrate
against recombinant HDAC2 is at the low micromolar ranges (Bradner et al., 2010,
Kilgore et al., 2010, Vogelauer et al., 2012). Moreover, our results demonstrated
that 10μM sodium butyrate significantly inhibited enzyme deacetylase activity of
HDAC2 but not the protein level of HDAC2 in SH-SY5Y cells. However, it was
reported that sodium butyrate at 1mM inhibited the higher HDAC2 protein level
and enzyme activity induced by high glucose in kidney epithelial-like cells (Du et
al., 2020). These results suggest that sodium butyrate may only serve as an inhibitor
of HDAC2 deacetylase activity at a lower dose, but can suppress the protein level
at the higher dosage.

Conclusion
Our results showed that the sodium butyrate, served as an HDAC2 enzyme inhibitor,
improved the BDNF expression, and prevented olanzapine-induced neuronal
lesions, including shorter neurite outgrowth and decreased spine density in
neuroblastoma cells and primary cortical neurons. Sodium butyrate at 10uM did
not affect the oxidative stress, lower Sirt1 expression, activation of NF-κB signaling
pathway, and overexpression of HDAC2 protein level induced by olanzapine.
Therefore, the mechanism of sodium butyrate’s neuroprotection effect on the
prevention of side effects induced by olanzapine was considered as the inhibition
of the enzyme activity of HDAC2 and enhancement of the expression of the
neurotrophic factor — BDNF.
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CHAPTER 4
Overall discussion and conclusion
Summary of key findings
The present study demonstrated that olanzapine inhibited neurite outgrowth in
neuroblastoma cells, and shortened dendritic length and decreased spine density in
the cultured primary cortical neurons (Table 4-1). The treatment of olanzapine
induced cellular and mitochondrial oxidative stress with lower expression of Sirt1.
Furthermore, olanzapine activated the NF-κB signaling pathway (overexpression
of p65 and phosphorylated p65) to upregulate the HDAC2 protein level. The mRNA
level and protein level of the neurotrophic factor, BDNF, was significantly
decreased in response to olanzapine in neurons. Therefore, olanzapine-induced
ROS/Sirt1-NF-κB-HDAC2 may contribute to the BDNF deficit and neurite lesions.
Importantly, sodium butyrate, as an HDAC2 inhibitor, ameliorated neuronal lesions
(decreased neurite outgrowth and spine density) and decreased BDNF expression
induced by olanzapine. However, sodium butyrate did not affect the redox state,
Sirt1 expression, NF-κB signaling pathway, and HDAC2 protein level. These
findings suggest that sodium butyrate prevents olanzapine-induced neuronal
lesions is mainly due to the inhibition of HDAC2 enzyme activity, thereby
increasing BDNF expression in neurons, rather than targeting the upstream
molecules, such as ROS, Sirt1, and NF-κB.

Overall discussion
Previous clinical studies reported that the lifelong medication of antipsychotic
drugs is associated with cognitive deficits in schizophrenia (Husa et al., 2014). In
rodents study, Ibi et al. (2017) found that long-term administration of clozapine
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Table 4-1 Summary of main findings in SH-SY5Y cells and cortical neurons
Parameters

Treatments
Morphology
Oxidative stress
Sirt1 protein level

SH-SY5Y cells

NF-κB signaling pathway

HDAC2
Protein level related to synaptogenesis
Morphology

Cortical neurons
mRNA level related to synaptogenesis

Butyrate

Olanzapine

Butyrate/Olanzapine

Neurite outgrowth

N.S.

↓***

↑##

Cellular ROS level

N.S.

↑*

↑*

Mitochondrial ROS level

N.S.

↑*

↑**

Sirt1

N.S.

↓*

↓*

P65

N.S.

↑*

↑*

P-p65

N/A

↑*

N/A

P50

N.S.

N.S.

N.S.

HDAC2 expression

N.S.

↑*

↑*

↓*

N/A

N/A

HDAC2 deacetylase activity
BDNF

N.S.

↓

↑#

Dendritic length

N.S.

↓***

↑##

↑**

↓**

↑###

BDNF

N.S.

↓**

↑##

MAP2

N.S.

N.S.

N.S.

Synaptophysin

N.S.

N.S.

N.S.

PSD95

N.S.

N.S.

N.S.

Dendritic spine density

*

***p < 0.001, **p < 0.01, *p < 0.05, versus the control group; ###p < 0.001, ##p < 0.01, #p < 0.05, versus the olanzapine group; N.S., no significance; N/A, experiments not
been developed.
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induced impairments in spatial memory capacity. The present study demonstrated
that olanzapine directly caused the impairment in neurite outgrowth in SH-SY5Y
cells (Figure 2-1) as well as the decreased total dendritic length and dendritic
spine density in the cortical neuron (Figure 3-2). Consistently, the in vitro or in
vivo studies confirmed that some other antipsychotic drugs induce neuronal
lesions. For example, haloperidol induced neurite deficits both in SH-SHY5Y
cell and cortical neurons (Hu et al., 2018). Also, the mice with the chronic
administration of clozapine showed the impairment in mature spine density (Ibi
et al., 2017). Therefore, it suggests that the impairment in neurogenesis and
synaptogenesis induced by antipsychotics administration may contribute to the
cognitive deficits (Huang and Song, 2019). Importantly, in the present study,
sodium butyrate prevented olanzapine-induced neuronal lesions in SH-SY5Y
cells and cortical neurons (Figure 3-1, 3-2). Consistently, the sodium butyrate
was proved that it promoted the neurogenesis in hippocampal neurons,
PC12-ND6 pheochromocytoma cells and dentate gyrus of mice (Yoo et al., 2011,
Uittenbogaard et al., 2018). Besides, the neuroprotection effect, as improvements
in synaptogenesis and cognition, of sodium butyrate has been certified in animal
models of Alzheimer's disease (Fischer et al., 2007). Furthermore, oral
administration of sodium butyrate has been applied in the clinical trial for
anti-inflammatory effects in humans with obesity (Cleophas et al., 2019).
Therefore, the sodium butyrate supplementation could be a novel treatment to
counteract the cognitive deficits induced by antipsychotic drugs for
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schizophrenic patients.

The present study showed that olanzapine elevated the ROS level both in the
intracellular level and mitochondrial level in the neurons (Figure 2-2). It was
further demonstrated that oxidative stress induced by olanzapine impaired
mitochondria,

and

stimulated

autophagic

clearance

of

dysfunctional

mitochondria in SH-SY5Y cells (Vucicevic et al., 2014). In the animal study, the
administration of antipsychotic drugs, such as olanzapine, clozapine, and
haloperidol, resulted in higher oxidants and lower antioxidants in rats (Bilgic et
al., 2017, Schröder et al., 2005). Oxidative stress induces deficits in
synaptogenesis and cognitive function (Liu et al., 2003). Therefore,
olanzapine-induced oxidative stress may contribute to mitochondria dysfunction,
the impairment of synaptogenesis, and cognition deficits. The Sirt1 is important
for synaptogenesis, while the inhibition of Sirt1 leads to the deficits in
synaptogenesis of neurons and impairments in cognitive function in mice
(Hisahara et al., 2008, Guo et al., 2011, Gao et al., 2010). In the present study,
the Sirt1 level was decreased in the neurons after the treatment of olanzapine.
Previous research showed that there is an interaction between oxidative stress and
Sirt1 (Alcendor et al., 2007). Therefore, the crosstalk between oxidative stress
and Sirt1 alteration induced by olanzapine may contribute to neuronal deficits.

However, the present study showed that the treatment of sodium butyrate at
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10μM did not inhibit the oxidative stress and prevent the decreased Sirt1
expression induced by olanzapine (Figure 3-5). Previously, it has been reported
that the dual effect of sodium butyrate as inhibition or stimulation of oxidative
stress. For example, 0.5mM and 1mM sodium butyrate decreased ROS level and
increased antioxidant enzyme level in NRK-52E cells (a rat renal proximal
tubular cell line) (Du et al., 2020). sodium butyrate at 0.2~0.4mM showed an
anti-oxidative stress effect in HepG2 cells (liver carcinoma cells) (Xing et al.,
2016). However, the higher dosage of sodium butyrate induced ROS
accumulation, as 4mM and 5mM sodium butyrate stimulated ROS accumulation
in Uuh7 hepatic cancer cells (Pant et al., 2017a, Pant et al., 2017b). Also, it
demonstrated that higher dosages of sodium butyrate (over 0.5mM) inhibited the
Sirt1 protein expression in 2D10 cells (a latently infected Jurkat T-cell line) (Das
et al., 2015). Therefore, sodium butyrate regulates ROS production and Sirt1
expression in a dose-dependent manner. Overall, it suggests that neuroprotective
effects of sodium butyrate at low dose in neurons does not depend on the
amelioration of oxidative stress and downregulated Sirt1 expression induced by
olanzapine.

It has been demonstrated that oxidative stress and downregulated Sirt1 result in
the activation of the NF-κB signaling pathway (Takada et al., 2003, Kauppinen
et al., 2013). The present study showed that olanzapine led to the overexpression
of p65 and phosphorylated p65 in SH-SY5Y neurons (Figure 2-3). This finding
in neurons was supported by an animal study, in which olanzapine induced
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stimulation of the NF-κB signaling pathway in the hypothalamus of rats (He et
al., 2019). The present study also demonstrated the HDAC2 was downstream of
NF-κB signaling pathway in neurons, since the expression of HDAC2 was
increased in SH-SY5Y cells transfected with p65 vectors (Figure 2-4). Moreover,
it was found that olanzapine caused overexpression of HDAC2 in SH-SY5Y cells.
Therefore, these findings suggest that the phosphorylation of p65 induced by
olanzapine could promote the translocation of NF-κB to upregulate the HDAC2
transcription. It is reported that HDAC2 can bind with histones near BDNF
promoters, which results in the inhibition of BDNF expression (Guan et al., 2009).
The present study found that olanzapine lowered the mRNA level of BDNF in
cortical neurons (Figure 3-3) and decreased the protein level of BDNF in
SH-SY5Y cells (Figure 2-5). These findings indicate that the mechanism of the
deficit of neurotrophic factor, BDNF, induced by olanzapine is via the activation
of the NF-κB-HDAC2 pathway (Figure 4-1).

Figure 4-1 Proposed mechanism of sodium butyrate protect the neuron from lesions caused
by olanzapine. Olanzapine induces oxidative stress with downregulation of Sirt1 protein, which
results in the activation of NF-κB signaling pathway. The translocated NF-κB leads to the
upregulation of HDAC2, which blocks the BDNF expression. Therefore, the neurite outgrowth
and dendritic spine density is decreased. Sodium butyrate may inhibit the deacetylase activity of
HDAC2 to protect the neuron from the damage induced by olanzapine.
72

While, in the present study, sodium butyrate at a low dose (10μM) did not inhibit
the activation of the NF-κB signaling pathway (Figure 3-6) and overexpression
of HDAC2 induced by olanzapine in the neuron. However, it has been reported
that higher dosages of sodium butyrate (0.1 and 0.5mM) blocked the activation
of NF-κB signaling pathway in colon carcinoma cells (Lee et al., 2017), and
sodium butyrate (1mM) inhibited higher expression of HDAC2 induced by
glucose in kidney epithelial cells (Du et al., 2020). This suggests that the
treatment of sodium butyrate affects the NF-κB pathway and HDAC2 protein
level in a dose-dependent manner. Importantly, the present study demonstrated
that the deacetylase activity of HDAC2 was inhibited by sodium butyrate at the
low micromolar range in neurons (Figure 3-4). Therefore, the sodium butyrate at
low dose in inhibition of deacetylase activity of HDAC2 may contribute to the
enhancement of BDNF expression and improvement of neuronal damages
induced by olanzapine. Overall, these findings suggest that inhibition of HDAC2
enzyme activity and upregulation of BDNF could be potential targets to prevent
neuronal lesions induced by antipsychotic drugs, while sodium butyrate could be
a potential compound combined with antipsychotic drugs to encounter cognitive
impairments for schipzophrenic patients.

Limitations and recommendations for future study
The present study suggests that sodium butyrate protect the neuron via inhibition
of HDAC2 deacetylase activity. However, sodium butyrate is not the specific
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HDAC2 inhibitor, HDAC2 shRNA should be used to confirm the specific role of
HDAC2 in the neuroprotective effect of sodium butyrate.

Although a study showed that HDAC2 binds to the promoter of BDNF (Guan et
al., 2009), the future experiment should include ChIP-assay to examine whether
olanzapine directly affects the binding between HDAC2 and the BDNF promoter.

The decreased spine density was shown in primary cortical neurons after
treatment with olanzapine, while the sodium butyrate ameliorated that effect.
Since mature spines, such as mushroom-shaped spines, have an important role in
the strengthening of the synapse, it should be further investigated that whether
olanzapine or sodium butyrate alter the density of the mushroom-shaped spines
by using high-resolution microscopy.

The present study was performed in vitro by using SH-SY5Y cells and primary
cortical neurons to examine the neurite outgrowth and synaptogenesis. The
results should be further confirmed in other neuroblastoma cell lines and animal
models. The cognitive index should be evaluated by behavior tests, such as
Morris water maze, Y maze, novel object recognition tests in rodents after
administration of olanzapine or sodium butyrate.

Conclusion and significance
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Cognitive deficits in schizophrenic patients are associated with the chronic
administration of antipsychotic drugs. This thesis demonstrated that olanzapine
induced reduction of neurite outgrowth and spine density, which may contribute
to cognitive deficits in clinical usage. The underlying mechanism is suggested
that olanzapine induces oxidative stress and declines Sirt1 expression, thereby
activation of the NF-κB signaling pathway, overexpression of HDAC2, and
inhibition of the BDNF transcription. Importantly, the sodium butyrate, as the
HDAC2 inhibitor, ameliorated the neuronal lesion and BDNF deficit induced by
olanzapine. Overall, this thesis provides evidence that olanzapine induces
neuronal lesions, while sodium butyrate can encounter antipsychotics-induced
adverse effects. These findings suggest that the supplementation of sodium
butyrate could serve as a potential novel therapeutic for clinical use to improve
the cognitive deficit induced by antipsychotic drugs.
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APPENDIX OF SUPPLEMENTARY METHODS
Preparation of the homogeneous buffer
0.5mM β-glycerophosphate (G-9422, Sigma Aldrich)
1mM phenylmethyl-sulfonyl fluoride (PMSF, P7626, Sigma Aldrich)
Protease inhibitor cocktail (100X, PIC, P-8340, Sigma Aldrich)
Dissolved in NP-40 cell lysis buffer (FNN0021, Thermofisher)

Preparation of the buffer used in the culture of primary cortical neuron
Dissection solution (500ml):
4g NaCl (S-7653, Sigma Aldrich)
0.2g KCl (P-9333, Sigma Aldrich)
12mg Na2HPO4 (S-7907, Sigma Aldrich)
15mg KH2PO4 (P-5379, Sigma Aldrich)
3g D-(+)-Glucose (G-8270, Sigma Aldrich)
7.5g Sucrose (S-9378, Sigma Aldrich)
Dissolved in 1M HEPES (H-7523, Sigma Aldrich), with pH=7.4 by using 1N
NaOH (S-8045, Sigma Aldrich)

Enzyme solution (100ml):
16 mg L-Cysteine (C-5360, Sigma Aldrich)
1000 units papain (P-4762, Sigma Aldrich)
140μl 0.1N NaOH
1ml 5mM 2-Amino-5-phosphonopentanoic acid (A5258, APV, Sigma Aldrich)
Dissolved in 100ml dissection buffer
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